

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 634 408 A1

(12)

EUROPEAN PATENT APPLICATION
published in accordance with Art.
158(3) EPC

(21) Application number: 93905622.2

(51) Int. Cl.⁶: C07D 273/00, C07D 413/10,
C07D 417/10, C07D 487/04,
C07D 487/08, A61K 31/395

(22) Date of filing: 08.03.93

(86) International application number:
PCT/JP93/00286(87) International publication number:
WO 93/19053 (30.09.93 93/24)(30) Priority: 17.03.92 JP 92070/92
15.10.92 JP 305093/92(43) Date of publication of application:
18.01.95 Bulletin 95/03(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE(71) Applicant: FUJISAWA PHARMACEUTICAL CO.,
LTD.

4-7, Doshomachi 3-chome
Chuo-ku
Osaka-shi
Osaka 541 (JP)

(72) Inventor: NISHIYAMA, Hitoshi
13-1-317, Kuzuharashinmachi
Neyagawa-shi,
Osaka 572 (JP)

Inventor: OHGAKI, Masaru
3-1-58-506, Minatojimanakamachi,
Chuo-ku
Kobe-shi,
Hyogo 650 (JP)


Inventor: YAMANISHI, Ryo
2-10, Midorigaoka 2-chome
Ikeda-shi,
Osaka 563 (JP)

Inventor: HARA, Toshihiko
565-19, Oaza Miyaji,
Miho-mura
Inashiki-gun,
Ibaraki 300-04 (JP)

(74) Representative: Türk, Dietmar, Dr. rer. nat.
Türk, Gille, Hrabal, Leifert
Patentanwälte
Brucknerstrasse 20
D-40593 Düsseldorf (DE)

(54) **DEPSIPEPTIDE DERIVATIVE, PRODUCTION THEREOF AND USE THEREOF.**

(57) A compound represented by general formula (I) or a salt thereof, excellent in parasitocidal activity as an anthelmintic for animal and man, wherein A represents benzyl which is appropriately substituted or phenyl which may be appropriately substituted; A^a represents benzyl or phenyl each of which may be appropriately substituted; B and D represent each lower alkyl; and C represents hydrogen or lower alkyl.

**BEST AVAILABLE COPY**

TECHNICAL FIELD


The present invention relates to new depsipeptide derivatives having antiparasitic activity.

5 BACKGROUND ART

Japanese Kokai Tokkyo Koho 3-35796 discloses depsipeptide derivative prepared by culturing microorganisms.

10 DISCLOSURE OF INVENTION

The object compound of the present invention, depsipeptide derivatives can be represented by the following general formula (I).



25 wherein A is benzyl group which has suitable substituent(s) or phenyl group which may have suitable substituent(s).

A^a is benzyl group which may have suitable substituent(s) or phenyl group which may have suitable substituent(s).

B and D are each lower alkyl,

30 C is hydrogen or lower alkyl.

According to the present invention, the object compound of depsipeptide derivatives (I) can be prepared by processes which are illustrated in the following schemes.

It should be indicated that any of D-configured compound, L-configured compound and/or DL-configured compound are in the extent of the present invention ; however, for the convenience, only D-configured compounds and L-configured compounds are explained in the process for preparation as follows.



40

45


50

55

Process 1




Process 2




(III)

nitration reaction




(Ia)

Process 3




(Ia)

reduction reaction




(Ib)

Process 4




10

alkylation reaction





25

Process 5




35

monoalkylation reaction followed by
intramolecular alkylation reaction




50

Process 6




(Ib)



hydroxylation reaction via
diaz compound


(Ie)

Process 7



(Ie)

alkylation reaction



(If)

wherein A, A³, B, C and D are each as defined above,

R is hydrogen or amino protective group,

A¹ is benzyl group which may have lower alkoxy,

A² is benzyl group which has nitro, or benzyl group which has nitro and lower alkoxy,

A³ is benzyl group which has amino, or benzyl group which has amino and lower alkoxy,

A⁴ is benzyl group which has mono- or di- lower alkylamino, or benzyl group which has mono- or di- lower alkylamino and lower alkoxy,

A⁵ is benzyl group which has cyclic amino, or benzyl group which has cyclic amino and lower alkoxy,

A⁶ is benzyl group which has hydroxy, or benzyl group which has hydroxy and lower alkoxy,

A⁷ is benzyl group which has lower alkoxy.

Throughout the present specification, the amino acid, peptides, protective groups, condensing agents, etc. are indicated by the abbreviations according to the IUPAC-IUB (Commission on Biological Nomenclature) which are in common use in the field of art.

Moreover, unless otherwise indicated, the amino acids and their residues when shown by such abbreviations are meant to be L-configured compounds and residues, and when shown by D-abbreviations,

they are meant to be D-configured compounds and residues.

In the present invention, there are employed the following abbreviations.

	p-MeOPhLac :	2-hydroxy-3-(4-methoxyphenyl)propionic acid [β -(p-methoxyphenyl)lactic acid]
5	Man :	2-hydroxyphenylacetic acid [mandelic acid]
	p-Me ₂ NPhLac :	3-(4-dimethylaminophenyl)-2-hydroxypropionic acid [β -(p-dimethylaminophenyl)lactic acid]
10	p-PipPhLac :	2-hydroxy-3-(4-piperazinophenyl)propionic acid [β -(p-piperazinophenyl)lactic acid]
	p-PyrPhLac :	2-hydroxy-3-(4-pyrrolidinophenyl)propionic acid [β -(p-pyrrolidinophenyl)lactic acid]
	p-NO ₂ PhLac :	3-(4-nitrophenyl)-2-hydroxypropionic acid [β -(p-nitrophenyl)lactic acid]
15	p-NH ₂ PhLac :	3-(4-aminophenyl)-2-hydroxypropionic acid [β -(p-aminophenyl)lactic acid]
	p-Et ₂ NPhLac :	3-(4-diethylaminophenyl)-2-hydroxypropionic acid [β -(p-diethylaminophenyl)lactic acid]
20	p-Hex ₂ NPhLac :	3-(4-di-n-hexylaminophenyl)-2-hydroxypropionic acid [β -(p-di-n-hexylaminophenyl)lactic acid]
	p-PylPhLac :	2-hydroxy-3-(1H-pyrrol-1-yl-phenyl)propionic acid [β -(p-1H-pyrrol-1-yl)phenyl]lactic acid]
	p-OHPhLac :	2-hydroxy-3-(4-hydroxyphenyl)propionic acid [β -(p-hydroxyphenyl)lactic acid]
25	p-EtOPhLac :	3-(4-ethoxyphenyl)-2-hydroxypropionic acid [β -(p-ethoxyphenyl)lactic acid]
	p-HexOPhLac :	3-(4-n-hexyloxyphenyl)-2-hydroxypropionic acid [β -(p-n-hexyloxyphenyl)lactic acid]
30	p-MEPhLac :	2-hydroxy-3-[4-(2-methoxyethoxy)phenyl]propionic acid [β -[p-(2-methoxyethoxy)phenyl]lactic acid]
	p-MEEPhLac :	2-hydroxy-3-{4-[2-(2-methoxyethoxy)ethoxy]Phenyl} propionic acid [β -{p-[2-(2-methoxyethoxy)ethoxy]phenyl}lactic acid]
	o-MeOPhLac :	2-hydroxy-3-(2-methoxyphenyl)propionic acid [β -(o-methoxyphenyl)lactic acid]
35	m-MeOPhLac :	2-hydroxy-3-(3-methoxyphenyl)propionic acid [β -(m-methoxyphenyl)lactic acid]
	3,4-DMOPhLac :	3-(3,4-dimethoxyphenyl)-2-hydroxypropionic acid [β -(3,4-dimethoxyphenyl)lactic acid]
40	2,4-DMOPhLac :	3-(2,4-dimethoxyphenyl)-2-hydroxypropionic acid [β -(2,4-dimethoxyphenyl)lactic acid]
	3,4-MODPhLac :	2-hydroxy-3-(3,4-methylenedioxyphenyl)propionic acid [β -(3,4-methylenedioxyphenyl)lactic acid]
	3-MA-4-MOPhLac :	3-(3-dimethylamino-4-methoxyphenyl)-2-hydroxypropionic acid [β -(3-dimethylamino-4-methoxyphenyl)lactic acid]
45	3,4-DMAPhLac :	3-[(3,4-bis(dimethylamino)phenyl)-2-hydroxyphenyl] propionic acid [β -[3,4-bis(dimethylamino)phenyl]lactic acid]
	o-FPhLac :	3-(2-fluorophenyl)-2-hydroxypropionic acid [β -(o-fluorophenyl)lactic acid]
50	m-FPhLac :	3-(3-fluorophenyl)-2-hydroxypropionic acid [β -(m-fluorophenyl)lactic acid]
	p-FPhLac :	3-(4-fluorophenyl)-2-hydroxypropionic acid [β -(p-fluorophenyl)lactic acid]
	Glycol :	Glycolic acid
55	PhLac :	2-hydroxy-3-phenylpropionic acid [β -phenyllactic acid]
	Lac :	2-hydroxypropionic acid [lactic acid]
	p-MorPhLac :	2-hydroxy-3-(4-morpholinophenyl)propionic acid

[β -(p-morpholinophenyl)lactic acid]

Suitable salts of the compound (I) are conventional non-toxic, pharmaceutically acceptable salt and may include a salt with a base or an acid addition salt such as a salt with an inorganic base, for example, an alkali metal salt (e.g. sodium salt, potassium salt, cesium salt, etc.), an alkali earth metal salt (e.g. calcium salt, magnesium salt, etc.), an ammonium salt; a salt with an organic base, for example, an organic amine salt (e.g. triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.), etc.; an inorganic acid addition salt (e.g. hydrochloride, hydrobromide, sulfate, phosphate, etc.); an organic carboxylic or sulfonic acid addition salt (e.g. formate, acetate, trifluoroacetate, maleate, tartrate, methanesulfonate, benzenesulfonate, p-toluenesulfonate, etc.); a salt with a basic or acidic amino acid (e.g. arginine, aspartic acid, glutamic acid, etc.); and the like.

In the above and subsequent descriptions of the present specification, suitable examples and illustrations of the various definitions which the present invention include within the scope thereof are explained in detail as follows.

The term "lower" is intended to mean 1 to 6 carbon atom(s), preferably 1 to 4 carbon atom(s), unless otherwise indicated.

Suitable substituent(s) in the term "benzyl group which has substituent(s)", "phenyl group which may have substituent(s)" and "benzyl group which may have substituent(s)" may include hydroxy, lower alkoxy, lower alkoxy lower alkoxy, lower alkoxy lower alkoxy lower alkoxy, halogen, lower alkyl, amino, cyclic amino, nitro, halogen (e.g. fluoro, chloro, bromo, iodo, etc.) and the like. These may have 1 or more than 2 substituents.

Suitable "lower alkyl" may include straight or branched one having 1 to 6 carbon atom(s) such as methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, and the like.

Suitable "lower alkoxy" may include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, pentyloxy, isopentyloxy, hexyloxy, and the like.

Suitable "lower alkoxy lower alkoxy" may include methoxymethoxy, methoxyethoxy, methoxypropoxy, ethoxyisopropoxy, and the like.

Suitable "lower alkoxy lower alkoxy lower alkoxy" may include methoxymethoxyethoxy, methoxyethoxyethoxy, methoxyethoxypropoxy, ethoxymethoxyisopropoxy, and the like.

Suitable "cyclic amino group" may be aromatic ring or alicyclic compound which have more than 1 nitrogen atom(s) as hetero atom(s), and it containing monocyclic group or condensed polycyclic group which may be saturated or unsaturated. Also, cyclic amino group may further contain hetero atom(s) such as more than 1 or 2 nitrogen atom(s), oxygen atom(s), sulfur atom(s), and the like and still further the cyclic amino group may be spiro ring or bridged cyclic compound. The number of the constructive atom(s) of cyclic amino group are not limited, but for example, monocyclic group have 3 to 8-membered rings and bicyclic have 7 to 11-membered rings.

Example of such cyclic amino group may include saturated or unsaturated monocyclic group which contain one nitrogen atom as hetero atom(s) such as 1-azetidiny, pyrrolidino, 2-pyrroline-1-yl, 1-pyrrolyl, piperidino, 1,4-dihydropyridine-1-yl, 1,2,5,6-tetrahydropyridine-1-yl, homopiperidino and the like, saturated or unsaturated monocyclic group which contain more than two nitrogen atom(s) as hetero atom(s) such as 1-imidazolidiny, 1-imidazolyl, 1-pyrazolyl, 1-triazolyl, 1-tetrazolyl, 1-piperazinyl, 1-homopiperazinyl, 1,2-dihydropyridazine-1-yl, 1,2-dihydropyrimidine-1-yl, perhydropyrimidine-1-yl, 1,4-diazacyclo heptane-1-yl, saturated or unsaturated monocyclic group which contain 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) as hetero atom(s) such as oxazolidine-3-yl, 2,3-dihydroisooxazole-2-yl, morpholino, saturated or unsaturated monocyclic group which contain 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s) as hetero atom(s) such as thiazolidine-3-yl, isothiazoline-2-yl, thiomorpholino, condensed polycyclic group such as indole-1-yl, 1,2-dihydrobenzimidazole-1-yl, perhydropyrrolo [1,2-a] pyrazine-2-yl, spirocyclic group such as 2-azaspiro [4,5] decane-2-yl, bridged cyclic heterocyclic group such as 7-azabicyclo [2,2,1] heptane-7-yl, and the like.

Said lower alkoxy, lower alkyl, amino, cyclic amino group and the like may have suitable substituent(s), such as lower alkylamino which is mono- or di- substituted, lower alkenyl, aralkyl, aryl, hydroxy, hydroxy lower alkyl, nitro, cyano, above mentioned cyclic amino, above mentioned lower alkoxy, lower alkoxy lower alkyl, halogen, halo lower alkyl, amino, protected amino, amino lower alkyl, protected amino lower alkyl, cyclo lower alkylamino, and the like.

The numbers of these substituent(s) are not limited, preferably 1 to 4, and the substituent(s) may be the same or not the same. Also two of the same or not the same substituent(s) may substitute the same atom(s) on cyclic amino group.

"Mono- or di- lower alkylamino group" may include amino group which has the group of one or two lower alkyl (e.g. methyl, ethyl, isopropyl, tert-butyl, tert-pentyl, etc.), preferably methylamino, ethylamino,

dimethylamino, diethylamino, di-n-propylamino, diisopropylamino, dibutylamino, etc..

"Lower alkenyl group" may include vinyl, allyl, isopropenyl, and the like. "Aalkyl group" may include benzyl, 1-phenylethyl, and the like.

"Aryl group" may include phenyl, naphthyl, and the like.

5 "Hydroxy lower alkyl group, alkoxy lower alkyl group, halo lower alkyl group, amino lower alkyl group, protected amino lower alkyl group" means that optional carbon atom(s) of above mentioned lower alkyl has each hydroxy, alkoxy, halogen, amino, protected amino.

"Amino protecting group", may include acyl such as lower alkanoyl (e.g. formyl, acetyl, propionyl, pivaloyl, hexanoyl, etc.), mono- (or di- or tri-) halo (lower) alkanoyl group (e.g. chloroacetyl, bromoacetyl, 10 dichloroacetyl, trifluoroacetyl, etc.), lower alkoxycarbonyl group, (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl, tert-pentyloxycarbonyl, hexyloxycarbonyl, etc.), carbamoyl group, aroyl group (e.g. benzoyl, toluoyl, naphthoyl, etc.), ar (lower) alkanoyl group (e.g. phenylacetyl, phenylpropionyl, etc.), aryloxycarbonyl group (e.g. phenoxycarbonyl, naphthylloxycarbonyl, etc.), aryloxy (lower) alkanoyl group (e.g. phenoxyacetyl, phenoxypropionyl, etc.), arylglyoxyloyl group, (e.g. phenylglyoxyloyl, naphthylglyoxyloyl, etc.), ar (lower) alkoxycarbonyl group which may have suitable substituent(s), (e.g. benzyloxycarbonyl, phenethylloxycarbonyl, p-nitrobenzyloxycarbonyl, etc.), ar (lower) alkylidene group which are 15 substituted or not substituted (e.g. benzylidene, hydroxybenzylidene etc.), ar (lower) alkyl group such as mono- (or di- or tri-) phenyl (lower) alkyl (e.g. benzyl, phenethyl, benzhydryl, trityl, etc.) and the like.

Above mentioned amino protective group contain the protective group which have the function to 20 temporarily protect amino group which is often used in the field of amino acid and peptide chemistry.

Suitable "benzyl group which has lower alkoxy" may include lower alkoxy substituted benzyl such as 4-methoxybenzyl, 2,4-dimethoxybenzyl, 3,4-dimethoxybenzyl, 3,4,5-trimethoxybenzyl, 2,3,4-trimethoxybenzyl, 2-ethoxybenzyl, 4-hexyloxybenzyl, etc.

Suitable "benzyl group which has halogen" may include halogen substituted benzyl such as 2-fluorobenzyl, 3-fluorobenzyl, 4-fluorobenzyl, 2-chlorobenzyl, 4-chlorobenzyl, 2,4-dichlorobenzyl, 3,4-dichlorobenzyl, 2,6-dichlorobenzyl, 2-bromobenzyl, 2-bromo-4-chlorobenzyl, etc. 25

Suitable "benzyl group which has lower alkyl" may include lower alkyl substituted benzyl such as 4-methylbenzyl, 4-ethylbenzyl, 4-propylbenzyl, 4-isopropylbenzyl, 4-butylbenzyl, 4-isobutylbenzyl, 4-tert-butylbenzyl, 4-pentylbenzyl, 4-hexylbenzyl, 2,3-dimethylbenzyl, 2,6-dimethylbenzyl, 3,4-dimethylbenzyl, 2,4,6-trimethylbenzyl, etc. 30

Suitable example of phenyl group which have such substituent(s) may include lower alkoxy substituted phenyl group (e.g. 4-methoxyphenyl, 3,4-dimethoxyphenyl, 3,4,5-trimethoxyphenyl, 2,3,4-trimethoxyphenyl, 2-ethoxyphenyl, 4-hexyloxyphenyl, etc.), halogen substituted phenyl (e.g. 2-chlorophenyl, 4-chlorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 2,6-dichlorophenyl, 2-bromophenyl, 2-bromo-4-chlorophenyl, 4-fluorophenyl, 2,4-difluorophenyl etc.), hydroxy substituted phenyl (e.g. 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, etc.), lower alkoxy- and hydroxy- substituted phenyl (e.g. 2-(hydroxymethoxy) phenyl, etc.). 35

Suitable example of benzyl group which have such substituent(s) may include lower alkoxy substituted benzyl (e.g. 4-methoxybenzyl, 3,4-dimethoxybenzyl, 3,4,5-trimethoxybenzyl, 2,3,4-trimethoxybenzyl, 2-ethoxybenzyl, 4-hexyloxybenzyl, etc.), halogen substituted benzyl (e.g. 2-chlorobenzyl, 4-chlorobenzyl, 2,4-dichlorobenzyl, 3,4-dichlorobenzyl, 2,6-dichlorobenzyl, 2-bromobenzyl, 2-bromo-4-chlorobenzyl, etc.), hydroxy substituted benzyl (e.g. 2-hydroxybenzyl, 3-hydroxybenzyl, 4-hydroxybenzyl, etc.), lower alkoxy and hydroxy substituted benzyl (e.g. 2-(hydroxymethoxy)benzyl, etc.). 40

More preferable example of "cyclic amino group which may have substituent(s)" may include pyrrolidino, morpholino, 1-piperazino, 4-methylpiperazino, piperidino and the like. 45

The processes for preparing the object compound (I) are explained in detail in the following.

Process 1

50 The object compound (I) or a salt thereof can be prepared by subjecting the compound (II) or its reactive derivative at the amino group or carboxy group or a salt thereof to cyclization reaction.

The starting compound (II), its reactive derivative or a salt thereof is new and such compounds can be prepared by the methods described in Preparation mentioned below or in substantially the same manner.

Suitable reactive derivative at the amino group of the compound (II) may include Schiff's base type 55 imino or its tautomeric enamine type isomer formed by the reaction of the compound (II) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (II) with a silyl compound such as bis(trimethylsilyl) acetamide, mono(trimethylsilyl)acetamide, bis(trimethylsilyl)urea or the like; a derivative formed by reaction of the compound (II) with phosphorus

trichloride or phosgene, and the like.

Suitable reactive derivative at the carboxy group of the compound (II) may include an acid halide, an acid anhydride, an activated amide, an activated ester, and the like. Suitable examples of the reactive derivatives may be an acid chloride; an acid azide; a mixed acid anhydride within acid such as a aliphatic carboxylic acid [e.g. acetic acid, propionic acid, butyric acid, trichloroacetic acid, etc.] or aromatic carboxylic acid [e.g. benzoic acid, etc.]; a symmetrical acid anhydride, and the like. These reactive derivatives can optionally be selected from them according to the kind of the compound (II) to be used. The reaction is usually carried out in the usual method which is used in cyclization reaction, under heating or in the presence of a conventional condensing agent. When R in the compound (II) is amino protective group, the elimination of the amino protective group is carried out previous to ring cyclization reaction.

Suitable condensing agent may include carbodiimide or a salt thereof [e.g. N,N'-dicyclohexylcarbodiimide, N-cyclohexyl-N'-morpholinoethylcarbodiimide, N-cyclohexyl-N'-(4-di-ethylaminocyclohexyl)-carbodiimide, N-ethyl-N'-(3-di-methylaminopropyl)carbodiimide or hydrochloride thereof, diphenyl phosphoryl azide, diethyl phosphorocyanidate, bis(2-oxo-3-oxazolidinyl)phosphinic chloride, etc.]; N,N'-carbonyldiimidazole, N,N'-carbonylbis-(2-methylimidazole); keteneimine compound (e.g. pentamethyleneketene-N-cyclohexylimine; diphenylketene-N-cyclohexylimine; ethoxyacetylene; 1-alkoxy-1-chloroethylen; ethyl polyphosphate; isopropyl polyphosphate; phosphorus oxychloride; phosphorus trichloride; thionyl chloride; oxalyl chloride; combining triphenylphosphine, and carbon tetrachloride or siazene carboxylate; 2-ethyl-7-hydroxybenzisoxazolium salt; 2-ethyl-5-(m-sulfophenyl)isoxazolium hydroxide intramolecular salt; 1-(p-chlorobenzenesulfonyloxy)-6-chloro-1H-benzotriazole; 1-hydroxybenzotriazole; so-called Vilsmeier reagent prepared by the reaction of N,N-dimethylformamide with thionyl chloride, phosgene, trichloromethyl chloroformate, phosphorus oxychloride, etc.; or the like.

The reaction in the presence of conventional condensing agent may be carried out in an organic solvent such as dichloromethane, methanol, ethanol, propanol, acetonitrile, pyridine, N,N-diethylformamide, 4-methyl-2-pentanone, tetrahydrofuran, benzene, toluene, xylene, etc. or any other solvent mixture which does not adversely influence the reaction.

The reaction temperature is not critical and the reaction is usually carried out under cooling to heating. Further, ring cyclization reaction under heating can be carried out to heat under boiling point in the solvent which is used in an organic solvent as above.

Process 2

The compound (Ia) or a salt thereof can be prepared by subjecting the compound (III) or a salt thereof to nitration reaction.

The starting compounds (III) contain known compounds (Japanese Kokai Tokkyo Koho No. 3-35796) and novel compounds. The novel compounds can be prepared by the procedures described in Preparations and Examples mentioned later or in substantially the same manner.

This reaction is carried out by reacting the compound (III) or a salt thereof with nitration agent (e.g. nitric acid, etc.).

The reaction can usually be carried out in a conventional solvent such as dichloromethane which does not adversely influence the reaction.

The reaction temperature is not critical and the reaction is usually carried out under cooling to heating.

This reaction can be carried out in substantially the same manner as Example 7 mentioned later.

Process 3

The object compound (Ib) or a salt thereof can be prepared by subjecting the compound (Ia) or a salt thereof to the reduction reaction.

This reaction can be carried out in a conventional manner for reducing nitro to amino, and it may include chemical reduction and catalytic reduction.

Suitable reducing agents to be used in chemical reduction are a combination of metal [e.g. tin, zinc, iron, etc.] or metallic compound [e.g. chromium chloride, chromium acetate, etc.] and an organic or inorganic acid [e.g. formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.].

Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts [e.g. platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.], palladium catalysts [e.g. spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.], nickel catalysts [e.g.

reduced nickel, nickel oxide, Raney nickel, etc.], cobalt catalysts [e.g. reduced cobalt, Raney cobalt, etc.], iron catalysts [e.g. reduced iron, Raney iron etc.], copper catalysts [e.g. reduced copper, Raney copper, Ullman copper, etc.] and the like.

The reduction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, methanol, ethanol, propanol, N,N-dimethylformamide, or a mixture thereof. Additionally, in case that the above-mentioned acid to be used in chemical reduction are in liquid, they can also be used as a solvent. Further, a suitable solvent to be used in catalytic reduction may be the above-mentioned solvent, and other conventional solvent such as diethyl ether, dioxane, tetrahydrofuran, etc., or a mixture thereof.

The reaction temperature of this reduction is not critical and the reaction is usually carried out under cooling to warming.

Process 4

The object compound (Ic) or a salt thereof can be prepared by subjecting the isolated or not isolated the compound (Ib) or a salt thereof, which is obtained by the Process 3, to alkylation reaction. This reaction can be carried out by combining aldehyde and reduction agent or alkylhalide and base. Suitable reduction agents are metallic hydride complex compound, [e.g. sodium borohydride, sodium cyanoborohydride, potassium borohydride, bis(2-methoxyethoxy)aluminium hydride, etc.], a combination of hydrogen, formic acid, or ammonium formate, and palladium catalysts [e.g. palladium on carbon, palladium hydroxide on carbon, palladium black, etc.].

Suitable base may include an inorganic base such as sodium bicarbonate, potassium carbonate, etc., or an organic base such as pyridine, triethylamine, etc. The reaction is usually carried out in a conventional solvent which does not adversely influence the reaction. The reaction which is combined by aldehyde and reduction agents can be carried out in substantially the same manner as Preparation 23 or Example 8 mentioned later, and the reaction which is combined by an alkyl halide and a base can be carried out in substantially the same manner as Preparation 41 mentioned later.

The reaction which is combined by the compound containing two aldehydes and reduction agents can be carried out in substantially the same manner as Example 31 mentioned later.

Process 5

The object compound (Id) or a salt thereof can be prepared by subjecting the isolated or not isolated compound (Ib) or a salt thereof, which is obtained by the Process 3, to mono alkylation reaction followed by intramolecular alkylation reaction. The reaction can be carried out by combining a compound, which has two aldehydes in the molecule, and reduction agents or by combining a compound, which has two halogens and a base.

Process 6

The object compound (Ie) or a salt thereof can be prepared by subjecting the isolated or not isolated object compound (Ib) or a salt thereof, which is obtained by the Process 3, to hydroxylation reaction by diazotization reaction followed by decomposition of diazonium salt. This reaction can be carried out by reacting the compound (Ib) or a salt thereof with sodium nitrite in the presence of an inorganic or an organic acid and decomposing a growing diazonium salt in water or an organic acid under the room temperature to heating, carrying out hydrolysis if necessary. It is possible to prepare the compound (Ie) or a salt thereof by transforming the amino group of the compound (Ib) or a salt thereof into a hydroxyl group. Suitable acid may include an inorganic acid [e.g. sulfuric acid, hydrochloric acid, borofluoric acid, etc.], and an organic acid [e.g. acetic acid, trifluoroacetic acid, etc.].

Process 7

The object compound (If) or a salt thereof can be prepared by subjecting the compound (Ie) or a salt, which is obtained by the Process 6, thereof to alkylation reaction. This reaction can be prepared by combining an alkylhalide and a base.

The reaction can be carried out substantially in the same manner as the later mentioned Example 15 and Example 16. Suitable base may include an inorganic base [e.g. sodium bicarbonate, potassium carbonate, etc. and an organic base [e.g. pyridine, triethylamine, etc.].

The compound or its salt of the present invention has excellent parasitocidal activities as an anthelmintic agent for animals and human bodies. It is effective to nematodes which are infected particularly to the domestic animals, domestic fowls or pets such as pigs, sheep, goats, cattle, horses, dogs, cats, and chickens.

Haemonchus genus, Trichostrongylus genus, Ostertagia genus, Nematodirus genus, Cooperia genus, Ascaris genus, Bunostomum genus, Oesophagostomum genus, Chabertia genus, Trichuris genus, Strongylus genus, Trichonema genus, Dictyocaulus genus, Capillaria genus, Heterakis genus, Toxocara genus, Ascaridia genus, Oxyuris genus, Ancylostoma genus, Uncinaria genus, Toxascaris genus, Parascaris genus, Nippostrongylus genus, Metastrongylus genus, Hyostrongylus genus, Strongyloides genus, Cyathostomum

genus. The parasitocidal activities are pointed out in some kind of Nematodirus genus, Cooperia genus, and Oesophagostomum genus which attack the intestinal tract, however, just Haemonchus genus and Ostertagia genus are parasitic on the stomach, and parasites of Dictyocaulus genus are found in lungs.

The parasites of Filariidae or Setariidae activities are found in heart and blood vessels, hypodermis, or lymphatic vessel or any other organisms or organs.

It is also effective to parasites which infect human beings. The most common parasites in the alimentary canal of human beings are as follows:

Ancylostoma genus, Necator genus, Ascaris genus, Strongyloides genus, Trichinella genus, Capillaria genus, Trichuris genus, and Enterobius genus.

It is also active for other medically important parasites, which is found in the blood or other organisms or organs out side of the alimentary canal, such as Wuchereria genus, Brugia genus, Onchocerca genus and Loa genus in Filariidae, as well as parasites such as Dracunculus genus in Dracunculidae. It is also active for parasites such as Strongyloides genus and Trichinella genus in the intestinal tract in a particular conditioned parasitism out side of intestinal tract.

Test

Test 1

(1) Test Compounds

The compounds which are illustrated in Example 1, Example 3, Example 4, Example 5, Example 10, Example 17, Example 23, Example 24, Example 25, and Example 29.

(2) Test

The effect of parasitocides was examined with the rats which was infected by nematodes which are parasitic on rats, Nippostrongylus brasilienses.

Wistar strain rats (female 6 weeks old, 120-130g weight) were sacrificed by infecting them and giving them subcutaneous injections of 3000 infective larvae per rat.

Test compound of 50mg was dissolved in 0.25ml dimethylsulfoxide, 0.5 % methylcellulose solution was added, and liquid volume was adjusted to be prescribed volume of 100, 10, 5, 2.5, 1.25, 1.0, 0.63, 0.32mg/kg to utilize. After they were infected, on each 7th, 8th, and 9th day, the test compound was administered orally with above concentration. On the 11th day, the rat was dissected and the numbers of parasites in the small intestines were measured.

The given measurement was based to calculate the reduction rate from the percentage of the numbers of the parasites of unadministered rats (control). The result of it is shown in the

Test 2

The reduction rate was calculated in a similar manner as Test 1 except when the test compound was subcutaneously administered to the rats instead of oral administration as in Test 1. The result of that is shown in the Table 2.

Test 3

For 1 rat, the 5000 infective larvae of Strongyloides venezuelensis were infected percutaneously to one group (2 rats) of 8 weeks old Mongolian gerbils. On the 10th day after they were infected, the suspended

test compound was orally administered once with the amount of established administration. The effect was judged according to the amount of the eggs in the feces or the numbers of worms in the intestinal tract. The measurement of the numbers of the eggs were taken from O ring method, and the numbers of the eggs (EPG) in 1g of feces were counted on the day before, on the day, and on the 1st, 2nd, 3rd, and 4th day after the administration. The numbers of the parasites were measured by dissecting Mongolian gerbils the 4th day after the administration (on the 14th day after infection). The method of measurement was followed by releasing the parasites, which live in the small intestines, into saline solution over night, and the released parasites were set to be as numbers of worms recovered.

The result (the mean number of each group) is shown in the Table 3.

Test Results :

Table 1

Test Compounds	Minimum Amount of Administration indicated by more than 95% of Reduction Rate
PF1022 (Japanese Patent Application 3-35796)	10 mg/kg
Example-1	2.5 mg/kg
Example-3	1.25mg/kg
Example-4	2.5 mg/kg
Example-5	0.63mg/kg
Example-10	2.5 mg/kg
Example-17	2.5 mg/kg
Example-23	5 mg/kg
Example-24	5 mg/kg
Example-25	5 mg/kg
Example-29	5 mg/kg

Table 2

Test Compounds	Minimum Amount of Administration indicated by more than 95% of Reduction Rate
PF1022 (Japanese Patent Application 3-35796)	> 100 mg/kg
Example-1	10 mg/kg
Example-3	5 mg/kg
Example-5	1.25mg/kg
Example-12	50 mg/kg

Table 3

Test Compounds	Dose	Change in Numbers of Parasites' Number of Eggs in Feces (EPG/100)						Numbers of the Worms recovered
		-2	0*	1	2	3	4	
Unadministered control	-	574	1240	1725	2343	1533	1505	3005
PF1022	20mg /kg	332	1615	581	1563	935	1005	3088
Example-5	5mg/ kg	455	1890	701	0	0	0	0
Example-5	2.5mg /kg	838	1665	452	0	0	0	0
Example-5	1.25 mg/ kg	551	2800	536	0	0	30	8

*) 0 stands for the starting day of administration.

When the compound of the present invention are used for animals and human being as an anthelmintic agent, it can be administered orally as a liquid drink. The liquid drink is usually suspended agent such as bentonite, and wetting agent, or other excipients with non-toxic solution, or solution made of water, suspension, or dispersed solution, and generally it comprises liquid drinks or antifoaming agent. The prescription of a liquid drink contains generally activated compound for 0.01-0.5 weight %, preferably 0.01-0.1 weight%. When it is preferably administered orally as a dried solid single dose, capsules, pills, or tablets, which comprise the desired amount of activated compounds are usually used. These forms of dosage are prepared by homogeneous admixtures of diluent, filler, disintegrator and/or excipient agents such as dextrine, lactose, talc, magnesium stearate, vegetable rubber, etc.

The usage of such single dose prescription can be varied broadly by kind of hosts, or kind of parasites, or weight of hosts which are to be treated and referring to the weight and containing quantity of anthelmintics.

When it is administered in animal feed, it is used as to disperse homogeneously, or as top dressing, or in the form of pellet. To achieve preferable effect of antiparasites, the activated compound of 0.0001-2% is usually contained in feed.

The dosage which was dissolved or dispersed in liquid carrier excipients can be administered to animals parenterally by giving them injections in the anterior stomach, muscle, tachea, or under the skin. The activated compound is mixed with suitable vegetable oil such as peanut oil or cottonseed oil for parontal administration. These prescriptions generally contain the activated compound of 0.05-50 weight%. It can also be administered locally by mixing in a suitable carrier such as dimethylsulfoxide or hydrocarbon solvent. The prepared solvents can be used directly on the exterior of animals by sprays or direct injections.

The most suitable usage amount of the activated compound to achieve the most effective result depends on the kind of animals, which are to be treated, and type of parasital infection and its stage. It can be achieved by oral administration of the activated compound 0.01-100mg, preferably 0.5-50.0mg, per kg of the treated animal. Such dosage amount is given in a relatively short term of 1-5days at once or separately.

The Preparations and Examples of the present invention are shown in the following.

Preparation 1

Boc-Tyr(Me)-OH (5.1g), was dissolved in 4N-hydrogen chloride in dioxane (87.5ml) and stirred under ice-cooling for 2 hours. After dioxane was evaporated in vacuo, the residue was dissolved in 6N-hydrochloric acid aqueous solution (45ml) and at 0°C, sodium nitrite (1.9g) was added by portions. After stirring for 4 hours, the reaction solution was extracted with ether (100ml × 3). After washing ether layer by saturated brine, the extract was dried over calcium chloride and the solvent was evaporated in vacuo. To the residue, benzene (30ml), benzyl alcohol (3.4ml) and p-toluenesulfonic acid mono hydrate (0.22g) were added and heated under reflux for 3 hours by using Dean Stark apparatus. After cooling down to the room temperature, the crude product, which was gained by evaporating the solvent, was purified by silica gel chromatography (eluting with ethyl acetate: hexane = 1:10, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain benzyl (S)-2-chloro-3-(4-methoxyphenyl)propionate

(1.79g).

NMR (CDCl₃, δ): 3.12 (dd, 1H), 3.29 (dd, 1H), 3.78 (s, 3H), 4.44 (t, 1H), 5.07-5.25 (m, 2H), 6.77-7.36 (m, 9H).

Preparation 2

5

To a solution of Boc-MeLeu-OH (1.37g) in methanol (30ml) and water (10ml) was added 20% aqueous cesium carbonate solution to be pH7.0. After the solvent was evaporated in vacuo, azeotroped three times by toluene (10ml). The residue was dissolved in dimethylformamide (20ml), under ice-cooling, benzyl(S)-2-chloro -3-(4-methoxyphenyl)propionate (1.7g) was added and stirred at room temperature for 24 hours. The reaction solution was poured into water (150ml), extracted with ether (100ml × 3), washed with saturated brine, and dried over anhydrous magnesium sulfate. The solvent was evaporated in vacuo, the resultant crude product was purified by silica gel chromatography, and eluted with mixture of ethyl acetate and hexane (1:8, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain Boc-MeLeu-D-p-MeOPhLac-OBzl (1.59g).

15 NMR (CDCl₃, δ): 0.90 (d, 6H), 1.41 (s) and 1.49 (s) (9H), 1.40-1.58 (m, 3H), 2.62-2.67 (m, 3H), 3.06-3.15 (m, 2H), 3.77 (s, 3H), 4.68-4.80 (m) and , 4.97-5.29 (m) (4H), 6.78 (d, 2H), 7.06 (d, 2H), 7.26-7.36 (m, 5H).

Preparation 3

20 To a solution of Boc-MeLeu-D-p-MeOPhLac-OBzl (1.36g) in methanol (15ml) was added 10% palladium on carbon (0.4g), and hydrogenated at atmospheric pressure of hydrogen gas for 45 minutes at ambient temperature. The catalyst was filtered off, the solvent was evaporated to give Boc-MeLeu-D-p-MeOPhLac-OH (1.08g).

25 NMR (CDCl₃, δ) : 0.89-0.95 (m, 6H), 1.44 (s, 9H), 1.44-1.79 (m, 3H), 2.66-2.82 (m, 3H), 3.01-3.20 (m, 2H), 3.79 (s, 3H), 4.40-4.75 (m, 1H), 5.15-5.38 (m, 1H), 6.82 (d, 2H), 7.14 (d, 2H).

Preparation 4

30 Boc-MeLeu-D-Lac-OBzl (1.04g) was dissolved in 4N-hydrogen chloride in dioxane (12.5ml), under ice-cooling stirred for 3 hours. After the solvent was evaporated in vacuo, azeotroped twice by toluene (10ml) to give H-MeLeu-D-Lac-OBzl·HCl (1g).

NMR (CDCl₃, δ) : 0.94-1.00 (m, 6H), 1.59 (d, 3H), 1.78-2.13 (m, 3H), 2.62-2.75 (m, 3H), 3.78-3.85 (m, 1H), 5.09-5.29 (m, 3H), 7.25-7.43 (m, 5H), 9.80-10.00 (m, 1H), 10.30-10.55 (m, 1H).

35 Preparation 5

To the mixture of Boc-MeLeu-D-p-MeOPhLac-OH (1g), H-MeLeu-D-Lac-OBzl·HCl (1g) in dichloromethane (20ml) and triethylamine (1.5ml) was added bis(2-oxo-3-oxazolidinyl) phosphinic chloride (0.98g), and was stirred for 13 hours. The water (50ml) was added to the mixture and it was extracted with ethyl acetate (50ml × 3). After it was washed with saturated brine, it was dried over anhydrous sodium sulfate. The solvent was evaporated in vacuo, the resultant crude product was purified by silica gel chromatography, and eluted with mixture of ethyl acetate and hexane (1: 3, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain Boc-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-OBzl (1.59g).

45 NMR (CDCl₃, δ): 0.80-0.99 (m, 12H), 1.42-1.80 (m, 18H), 2.66-3.04 (m, 8H), 3.78 (s, 3H), 4.64-5.43 (m, 6H), 6.81 (d, 2H), 7.12-7.39 (m, 7H).

Preparation 6

50 Boc-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-OBzl was used instead of Boc-MeLeu-D-p-MeOPhLac-OBzl. Except above matter, Boc-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-OH (0.67g) was obtained according to a similar manner to that of Preparation 3.

NMR (CDCl₃, δ) : 0.82-0.94 (m, 12H), 1.46 (s, 9H), 1.40-1.80 (m, 9H), 2.67-3.29 (m, 8H), 3.77 (s, 3H), 4.83-5.71 (m, 4H), 6.80 (d, 2H), 7.15 (d, 2H).

55

Preparation 7

Boc-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-OBzl (0.75g) was dissolved in 4N-hydrogen chloride in ethyl acetate (5.25ml), and it was stirred under ice-cooling for three hours. After the solvent was evaporated in vacuo, it was azeotroped twice by toluene (10ml) to give H-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-OBzl·HCl (0.74g).

NMR (CDCl₃, δ) : 0.77-1.00 (m, 12H), 1.21-1.98 (m, 9H), 2.61-3.10 (m, 8H), 3.77 (s, 3H), 3.62-3.82 (m, 1H), 5.04-5.55 (m, 5H), 6.83 (d, 2H), 7.12-7.34 (m, 7H), 9.30-9.50 (m, 1H), 10.40-10.59 (m, 1H).

Preparation 8

Boc-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-OH (0.67g) was used instead of Boc-MeLeu-D-p-MeOPhLac-OH. H-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-OBzl·HCl (0.74g) was used instead of H-MeLeu-D-Lac-OBzl·HCl. Except above matter, Boc-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-OBzl (0.94g) was obtained according to a similar manner to that of Preparation 5.

NMR (CDCl₃, δ) : 0.80-0.99 (m, 24H), 1.10-1.70 (m, 27H), 2.65-3.10 (m, 16H), 3.77 (s, 6H), 4.61-5.49 (m, 10H), 6.78-6.85 (m, 4H), 7.12-7.40 (m, 9H).

Preparation 9

Boc-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-OBzl (0.92g) was used instead of Boc-MeLeu-D-p-MeOPhLac-OBzl. Except above matter, Boc-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-OH (0.89g) was obtained according to a similar manner to that of Preparation 3.

NMR (CDCl₃, δ) : 0.79-0.99 (m, 24H), 1.10-1.80 (m, 27H), 2.65-3.10 (m, 16H), 3.77 (s, 6H), 4.60-5.65 (m, 8H), 6.78-6.90 (m, 4H), 7.13-7.25 (m, 4H).

Preparation 10

To a solution of Boc-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-OH (0.89g) and pentafluorophenol (0.14g) in dichloromethane (10ml) were added under ice-cooling, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide·hydrochloride (0.22g), and stirred for 3 hours. The solvent was evaporated in vacuo, the resultant crude product was purified by silica gel chromatography, and eluted with mixture of ethyl acetate and hexane (1:1, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain Boc-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-OC₆F₅ (0.8g).

NMR (CDCl₃, δ) : 0.80-0.99 (m, 24H), 1.10-1.80 (m, 27H), 2.65-3.18 (m, 16H), 3.77 (s, 6H), 4.60-5.55 (m, 8H), 6.78-6.90 (m, 4H), 7.10-7.22 (m, 4H).

Preparation 11

To a solution of H-D-Man-OH (1g) and triethylamine (0.92ml) in ethyl acetate (50ml) was added phenacyl bromide (1.31g) under ice-cooling. After the mixture was stirred for 48 hours at room temperature, the reaction mixture was poured into water and was extracted with ethyl acetate (50ml × 3). After the extract was dried over anhydrous magnesium sulfate, it was concentrated in vacuo to give H-D-Man-OPac (1.7g).

NMR (CDCl₃, δ) : 5.30 (d, 1H), 5.41 (s, 1H), 5.47 (d, 1H), 7.37-7.88 (m, 10H).

Preparation 12

To a solution of Boc-MeLeu-OH (1.54g), and H-D-Man-OPac (1.7g) in methylene chloride (50ml) were added dimethylaminopyridine (77mg) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide·hydrochloride (1.32g) under ice-cooling. The mixture was stirred for 3 hours successively. After methylene chloride was evaporated in vacuo, ethyl acetate (200ml) was added, and washed with water, the solution was dried over anhydrous magnesium sulfate. The solvent was evaporated in vacuo, the resultant crude product was purified by silica gel chromatography, and eluted with mixture of ethyl acetate and hexane (1:3, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain Boc-MeLeu-D-Man-OPac (3g).

NMR (CDCl₃, δ) : 0.91-0.97 (m, 6H), 1.39 (s) and 1.43 (s) (9H), 1.40-1.86 (m, 3H), 2.85 (s) and 2.88 (s) (3H), 4.80-4.88 (m) and 5.04-5.12 (m) (1H), 5.29 (d, 1H), 5.40 (d, 1H), 6.11 (s) and 6.15 (s) (1H), 7.40-7.86 (m, 10H).

Preparation 13

5

To 90% aqueous acetic acid (30ml) of Boc-MeLeu-D-Man-OPac (3g) was added zinc powder (3g) and stirred for 1 hour at room temperature. After filtering the zinc residue, the solvent was evaporated in vacuo. Ethyl acetate (200ml) was added to the residue, and washed with 10 % aqueous citric acid, water, and saturated brine. After drying over anhydrous magnesium sulfate. The solvent was evaporated in vacuo, the resultant crude product was purified by silica gel chromatography, and eluted with mixture of methylene chloride, ethanol and acetic acid (20: 1:0.1, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain Boc-MeLeu-D-Man-OH (2.22g).

10

NMR (CDCl₃, δ) : 0.91-0.97 (m, 6H), 1.28 (s) and 1.44 (s) (9H), 1.40-1.80 (m, 3H), 2.86 (s, 3H), 4.80-4.98 (m, 1H), 5.95 (s, 1H), 7.39-7.50 (m, 5H).

15

Preparation 14

Trichloroethyl (S)-2-chloropropionate (4.8g) was used instead of benzyl (S)-2-chloro-3-(4-methoxyphenyl) propionate. Except above matter, Boc-MeLeu-D-Lac-OTce (7.98g) was obtained according to a similar manner to that of Preparation 2.

20

NMR (CDCl₃, δ) : 0.93-0.98 (m, 6H), 1.47 (s, 9H), 1.59 (d, 3H), 1.50-1.78 (m, 3H), 2.81 (s) and 2.84 (s) (3H), 4.64-5.05 (m, 3H), 5.19 (q, 1H).

Preparation 15

25

Boc-MeLeu-D-Lac-OTce (2.7g) was used instead of Boc-MeLeu-D-Lac-OBzl. Except above matter, H-MeLeu-D-Lac-OTce·HCl (2.45g) was obtained according to a similar manner to that of Preparation 4.

NMR (CDCl₃, δ) : 0.95-1.03 (m, 6H), 1.68 (d, 3H), 1.80-2.16 (m, 3H), 2.74-2.80 (m, 3H), 3.80-3.99 (m, 1H), 4.67 (d, 1H), 4.96 (d, 1H), 5.32 (q, 1H), 9.80-10.10 (m, 1H), 10.30-10.60 (m, 1H).

30

Preparation 16

Boc-MeLeu-D-Man-OH (2.22g) was used instead of Boc-MeLeu-D-p-MeOPhLac-OH. H-MeLeu-D-Lac-OTce·HCl (2.4g) was used instead of H-MeLeu-D-Lac-OBzl·HCl. Except above matter, Boc-MeLeu-D-Man-MeLeu-D-Lac-OTce (3.33g) was obtained according to a similar manner to that of Preparation 5.

35

NMR (CDCl₃, δ) : 0.77-0.99 (m, 12H), 1.35 (s, 9H), 1.26-1.84 (m, 9H), 2.79-2.98 (m, 6H), 4.53-5.55 (m, 5H), 6.15-6.24 (m, 1H), 7.39-7.46 (m, 5H).

Preparation 17

40

Boc-MeLeu-D-Man-MeLeu-D-Lac-OTce (1.5g) was used instead of Boc-MeLeu-D-Man-OPac. Except above matter, Boc-MeLeu-D-Man-MeLeu-D-Lac-OH (1.46g) was obtained according to a similar manner to that of Preparation 13.

NMR (CDCl₃, δ) : 0.79-0.99 (m, 12H), 1.37 (s, 9H), 1.20-1.83 (m, 9H), 2.79-2.96 (m, 6H), 4.53-5.40 (m, 3H), 6.14-6.26 (m, 1H), 7.39-7.44 (m, 5H).

45

Preparation 18

Boc-MeLeu-D-Man-MeLeu-D-Lac-OTce (1.5g) was used instead of Boc-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-OBzl. Except above matter, H-MeLeu-D-Man-MeLeu-D-Lac-OTce·HCl (1.3g) was obtained according to a similar manner to that of Preparation 7.

50

NMR (CDCl₃, δ) : 0.78-0.98 (m, 12H), 1.30-2.24 (m, 9H), 2.78-2.97 (m, 6H), 3.79-3.99 (m, 1H), 4.52-5.56 (m, 4H), 6.27-6.31 (m, 1H), 7.40-7.52 (m, 5H), 9.52-9.90 (m, 1H), 10.10-10.42 (m, 1H).

Preparation 19

Boc-MeLeu-D-Man-MeLeu-D-Lac-OH (1.4g) was used instead of Boc-MeLeu-D-p-MeOPhLac-OH. H-MeLeu-D-Man-MeLeu-D-Lac-OTce·HCl (1.3g) was used instead of H-MeLeu-D-Lac-OBzl·HCl. Except

above matter, Boc-MeLeu-D-Man-MeLeu-D-Lac-OTce (1.7g) was obtained according to a similar manner to that of Preparation 5.

NMR (CDCl_3, δ) : 0.76-1.18 (m, 24H), 1.21-1.98 (m, 27H), 2.79-3.10 (m, 12H), 4.52-5.59 (m, 8H), 6.13-6.25 (m, 2H), 7.15-7.55 (m, 10H).

Preparation 20

Boc-MeLeu-D-Man-MeLeu-D-Lac-MeLeu-D-Man-MeLeu-D-Lac-OTce was used instead of Boc-MeLeu-D-Man-OPac. Except above matter, Boc-MeLeu-D-Man-MeLeu-D-Lac-MeLeu-D-Man-MeLeu-D-Lac-OH (1.07g) was obtained according to a similar manner to that of Preparation 13.

NMR (CDCl_3, δ) : 0.70-1.10 (m, 24H), 1.35 (s, 9H), 1.25-1.98 (m, 18H), 2.78-3.09 (m, 12H), 4.20-5.59 (m, 6H), 6.10-6.37 (m, 2H), 7.26-7.59 (m, 10H).

Preparation 21

Boc-MeLeu-D-Man-MeLeu-D-Lac-MeLeu-D-Man-MeLeu-D-Lac-OH was used instead of Boc-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-OH. Except above matter, Boc-MeLeu-D-Man-MeLeu-D-Lac-MeLeu-D-Man-MeLeu-D-Lac-OC₆F₅ (0.96g) was obtained according to a similar manner to that of Preparation 10.

NMR (CDCl_3, δ) : 0.72-1.00 (m, 24H), 1.10-1.95 (m, 27H), 2.77-3.09 (m, 12H), 4.40-5.68 (m, 6H), 6.12-6.24 (m, 2H), 7.22-7.58 (m, 10H).

Preparation 22

To a solution of ethyl (R)-2-acetoxy-3-(4-nitrophenyl)propionate (5.62g) in ethanol (50ml) were added concentrated hydrochloric acid (2.5ml) and 10% palladium on carbon (0.6g). The mixture was hydrogenated under atmospheric pressure of hydrogen gas for 3 hours at room temperature. The catalyst was filtered off and the solvent was evaporated in vacuo. To the residue was added 0.05N hydrochloric acid (200ml) and washed with ether (100ml \times 2). Saturated aqueous sodium hydrogencarbonate was added to water layer until pH10, and extracted with ether (100ml \times 4). After the ether layer was washed with saturated brine, it was dried over anhydrous magnesium sulfate and evaporated in vacuo. To the residue, benzene (40ml), benzylalcohol (21ml) and p-toluenesulfonic acid \cdot mono hydrate (4.76g) were added, and the mixture was heated under reflux for 4 hours. After ice-cooling down to room temperature, the solvent was evaporated in vacuo. To the residue was added water (200ml) and washed with ether (100ml \times 2). Saturated aqueous sodium hydrogencarbonate was added to water layer until pH10, extracted with ether (100ml \times 4). After the ether layer was washed with saturated brine, it was dried over anhydrous magnesium sulfate and the solvent was evaporated in vacuo to give benzyl (R)-3-(4-aminophenyl)-2-hydroxypropionate (2.84g).

NMR (CDCl_3, δ) 2.85 (dd, 1H), 2.6-3.6 (m, 3H), 3.00 (dd, 1H), 4.38 (dd, 1H), 5.15 (s, 2H), 6.53 (d, 2H), 6.90 (d, 2H), 7.25-7.4 (m, 5H) IR (neat): 1740 cm^{-1}

Preparation 23

To a solution of benzyl (R)-3-(4-aminophenyl)-2-hydroxypropionate (0.26g) in acetic acid (6ml) was added paraformaldehyde (0.3g), and further sodium cyanoborohydride (0.3g) was added gradually, and stirred for 3 hours. To the solution of sodium bicarbonate (25ml) and ice (25g) was added reaction mixture gradually and was extracted with ethyl acetate (50ml \times 2). After washing the ethyl acetate layer with saturated brine, it was dried over anhydrous magnesium sulfate. The solvent was evaporated in vacuo, the resultant crude product was purified by silica gel chromatography, and eluted with mixture of ethyl acetate and hexane (7 : 3, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain benzyl (R)-3-(4-dimethylaminophenyl)-2-hydroxypropionate (0.22g). NMR (CDCl_3, δ) 2.64 (d, 1H), 2.91 (s, 6H), 2.90 (dd, 1H), 3.04 (dd, 1H), 4.43 (ddd, 1H), 5.18 (s, 2H), 6.63 (d, 2H), 7.01 (d, 2H), 7.35 (bs, 5H) IR (neat): 1733, 1612 cm^{-1}

Preparation 24

To a solution of Boc-MeLeu-OH (1.27g), H-D-p-Me₂NPhLac-OBzl (1.47g) in methylene chloride (20ml) were added under ice-cooling, dimethylaminopyridine (0.15g), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide \cdot hydrochloride (1.01g), and stirred for 15 hours successively. The solvent was evaporated in

vacuo. The water (50ml) was added to residue and extracted with ethyl acetate (50ml x 3). After the ethyl acetate layer was washed with saturated brine, and dried over anhydrous sodium sulfate. The solvent was evaporated in vacuo, the resultant crude product was purified by silica gel chromatography, and eluted with mixture of ethyl acetate and hexane (4:1, v/v). The fractions containing the desired product were combined

5 and evaporated in vacuo to give Boc-MeLeu-D-p-Me₂NPhLac-OBzl (1.69g).

NMR (CDCl₃, δ) 0.90 (d, 6H), 1.4-1.65 (m, 12H), 2.63 (s) and 2.68 (s) (3H), 2.93 (s, 6H), 3.05-3.15 (m, 2H), 4.65-4.80 (m) and 4.95-5.20 (m) (4H), 6.62 (d, 2H), 7.03 (d, 2H), 7.1-7.2 (m, 5H)

IR (KBr): 1747, 1730, 1693, 1675, cm⁻¹

10 Preparation 25

To a solution of Boc-MeLeu-D-p-Me₂NPhLac-OBzl (1.67g) in methanol (30ml) and tetrahydrofuran (5ml) was added 10 % palladium on carbon (0.3g), and hydrogenation was done in hydrogen gas under atmospheric pressure for 1 and 0.5 hour. After catalyst was filtrated, the solvent was evaporated in vacuo to

15 give Boc-MeLeu-D-p-Me₂NPhLac-OH (1.44g).

IR (KBr): 1741, 1694, cm⁻¹

Preparation 26

20 To a mixture of Boc-MeLeu-D-p-Me₂NPhLac-OH (1.44g) in triethylamine (1.92ml) and dichloromethane (15ml) was added under ice-cooling, bis (2-oxo-3-oxazolidinyl)phosphinic chloride (1.30g) and stirred successively for 15 and 1/2 hours. The solvent was evaporated in vacuo, and water (50ml) was added and extracted with ethyl acetate (50ml x 3). The ethyl acetate layer was washed with saturated brine, dried over anhydrous sodium sulfate. The solvent was evaporated in vacuo, the resultant crude product was purified

25 by silica gel chromatography, and eluted with mixture of ethyl acetate and hexane (7:3, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl (1.55g).

NMR (CDCl₃, δ) 0.8-1.0 (m, 12H), 1.4-1.7 (m, 18H), 2.7-3.1 (m, 8H), 2.90 (s, 6H), 5.65-6.5 (m, 6H), 6.65 (d, 2H), 7.08 (d, 2H), 7.3-7.4 (m, 5H)

30 IR (KBr): 1740, 1695, 1663, cm⁻¹

Preparation 27

Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl (0.77g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OH (637mg) was obtained according to a similar manner to that of Preparation 25.

35 IR (KBr): 1739, 1694, 1663, cm⁻¹

Preparation 28

40 Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl (765mg) was dissolved in 4N hydrogen chloride in ethyl acetate (5ml), and stirred for 2 hours at room temperature. After the solvent was evaporated in vacuo, it was azeotroped twice with toluene (10ml) to obtain 2HCl·H-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl (783mg)

45 IR (KBr): 1744, 1647, cm⁻¹

Preparation 29

Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OH (0.64g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH, 2HCl·H-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl (0.78g) was used instead of HCl·H-MeLeu-D-Lac-OBzl. Except above matter, Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl (0.88g) was obtained according to a similar manner to that of Preparation 26.

50 NMR (CDCl₃, δ) 0.75-1.0 (m, 24H), 1.2-1.8 (m, 27H), 2.65-3.1 (m, 16H), 2.91 (s, 12H), 4.65-5.5 (m, 10H), 6.6-6.75 (m, 4H), 7.0-7.15 (m, 4H), 7.3-7.7 (m, 5H)

IR (KBr): 1740, 1694, 1662, cm⁻¹

FAB-MS: 1243 [M + H]⁺

Preparation 30

Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl (0.87g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OH (0.81g) was obtained according to a similar manner to that of Preparation 25.
IR (KBr): 1735,1695,1662cm⁻¹

Preparation 31

Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OH (0.81g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl. Except above matter, 3HCl·H-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OH (0.826g) was obtained according to a similar manner to that of Preparation 28.
IR (KBr): 1743,1646cm⁻¹

Preparation 32

The suspended solution of benzyl (R)-3-(4-aminophenyl)-2-hydroxypropionate (0.27g), bis(2-chloroethyl)ether (0.12ml), potassium carbonate (0.28g), and sodium iodide (0.075g) in dimethylformamide (1ml) were heated at 70-90 °C for 7 hours. After cooling it down to room temperature, water (50ml) was added and extracted with ether (25ml × 3). After the ether layer was washed with saturated brine, it was dried over anhydrous sodium sulfate. The solvent was evaporated in vacuo, the resultant crude product was purified by silica gel column chromatography, and eluted with mixture of hexane, ethyl acetate and ethanol (60:35:5, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain benzyl (R)-2-hydroxy-3-(4-morpholinophenyl)propionate (0.14g).
NMR (CDCl₃, δ) 2.66 (d, 1H), 2.91 (dd, 1H), 3.05 (dd, 1H), 3.0-3.15 (m, 4H), 3.8-3.95 (m, 4H), 4.45 (ddd, 1H), 5.18 (s, 2H), 6.79 (d, 2H), 7.05 (d, 2H), 7.3-7.4 (m, 5H)
IR (neat): 1734cm⁻¹
EI-MS : 341 [M]⁺

Preparation 33

H-D-p-MorPhLac-OBzl (0.90g) was used instead of H-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-OBzl (1.36g) was obtained according to a similar manner to that of Preparation 24.
NMR (CDCl₃, δ) 0.9 (d, 6H), 1.4-1.65 (m, 12H), 2.63 (s) and 2.66 (s) (3H), 3.05-3.2 (m, 6H), 3.85-3.95 (m, 4H), 4.7-4.8 (m) and 4.95-5.25 (m) (4H), 6.80 (d, 2H), 7.07 (d, 2H), 7.1-7.2 (m, 5H)
IR (KBr): 1740,1695cm⁻¹

Preparation 34

Boc-MeLeu-D-p-MorPhLac-OBzl (1.35g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-p-MorPhLac-OH (1.08g) was obtained according to a similar manner to that of Preparation 25.
IR (KBr): 1742,1695cm⁻¹

Preparation 35

Boc-MeLeu-D-p-MorPhLac-OH (1.08g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH. Except above matter, Boc-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-OBzl (1.49g) was obtained according to a similar manner to that of Preparation 26.
NMR (CDCl₃, δ) 0.85-0.95 (m, 12H), 1.4-1.7 (m, 18H), 2.78 (s), 2.81 (s) and 2.88 (s) (6H), 3.0-3.1 (m, 2H), 3.1-3.15 (m, 4H), 3.85-3.9 (m, 4H), 4.65-4.75 (m) and 4.9-5.5 (m) (6H), 6.82 (d, 2H), 7.13 (d, 2H), 7.3-7.4 (m, 5H)
IR (KBr): 1740,1694,1662cm⁻¹

Preparation 36

Boc-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-OBzl (0.74g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-OH (0.64g) was obtained according to a similar manner to that of Preparation 25.

IR (KBr): 1741,1694,1664cm⁻¹

Preparation 37

Boc-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-OBzl (0.74g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl. Except above matter, 2HCl•H-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-OBzl (0.73g) was obtained according to a similar manner to that of Preparation 28.

IR (KBr): 1744,1648cm⁻¹

Preparation 38

Boc-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-OH (0.64g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH, 2HCl•H-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-OBzl (0.73g) was used instead of HCl•H-MeLeu-D-Lac-OBzl. Except above matter, Boc-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-OBzl (1.08g) was obtained according to a similar manner to that of Preparation 26.

NMR (CDCl₃, δ) 0.8-1.05 (m, 24H), 1.15-1.8 (m, 27H), 2.65-3.2 (m, 24H), 3.8-3.95 (m, 8H), 4.65-4.75 (m) and 4.9-5.5 (m) (10H), 6.75-6.9 (m, 4H), 7.05-7.2 (m, 4H), 7.3-7.4 (m, 5H)

IR (KBr): 1738,1694,1663cm⁻¹

FAB-MS: 1227 [M + H]⁺

Preparation 39

Boc-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-OBzl (1.07g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-OH (0.96g) was obtained according to a similar manner to that of Preparation 25.

IR (KBr): 1739,1694,1663cm⁻¹

Preparation 40

Boc-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-OH (0.96g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl. Except above matter, 3HCl•H-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-OH (1.02g) was obtained according to a similar manner to that of Preparation 28.

IR (KBr): 1741,1646cm⁻¹

Preparation 41

The suspended solution of benzyl (R)-3-(4-aminophenyl)-2-hydroxypropionate (1.53g), 1,4-dibromobutane (0.61ml), potassium carbonate (2.07g) and sodium iodide (0.37g) in dimethylformamide (5ml) were stirred at room temperature for 71 hours. To the solution was added water (50ml) and extracted with ether (50ml, 25ml × 2). After the ether layer was washed with saturated brine, it was dried over anhydrous sodium sulfate. The solvent was evaporated in vacuo, the resultant crude product was purified by silica gel column chromatography, and eluted with mixture of hexane and ethyl acetate (4 : 1, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain benzyl (R)-2-hydroxy-3-(4-pyrrolidinophenyl)propionate (1.35g).

NMR (CDCl₃, δ) 1.95-2.05 (m, 4H), 2.61 (d, 1H), 2.90 (dd, 1H), 3.03 (dd, 1H), 3.2-3.3 (m, 4H), 4.43 (ddd, 1H), 5.18 (s, 2H), 6.45 (d, 2H), 6.99 (d, 2H), 7.3-7.4 (m, 5H)

IR (neat): 1732cm⁻¹

Preparation 42

H-D-p-PyrPhLac-OBzl (1.34g) was used instead of H-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-p-PyrPhLac-OBzl (1.79g) was obtained according to a similar manner to that of Preparation 24.

NMR (CDCl₃, δ) 0.92 (d, 6H), 1.4-1.65 (m, 12H), 1.95-2.1 (m, 4H), 2.47 (s) and 2.52 (s) (3H), 3.0-3.15 (m, 2H), 3.2-3.35 (m, 4H), 4.7-4.8 (m) and 5.0-5.25 (m) (4H), 6.46 (d, 2H), 7.02 (d, 2H), 7.1-7.2 (m, 5H)
IR (KBr): 1750, 1740, 1692, 1672 cm⁻¹

Preparation 43

Boc-MeLeu-D-p-PyrPhLac-OBzl (1.78g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-p-PyrPhLac-OH (1.44g) was obtained according to a similar manner to that of Preparation 25.

IR (KBr): 1740, 1695 cm⁻¹

Preparation 44

Boc-MeLeu-D-p-PyrPhLac-OH (1.44g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH. Except above matter, Boc-MeLeu-D-p-PyrPhLac-MeLeu-D-Lac-OBzl (1.53g) was obtained according to a similar manner to that of Preparation 26.

NMR (CDCl₃, δ) 0.8-0.95 (m, 12H), 1.4-1.7 (m, 18H), 1.95-2.05 (m, 4H), 2.7-3.05 (m, 8H), 3.2-3.3 (m, 4H), 5.65-5.75 (m) and 5.9-6.5 (m) (6H), 6.47 (d, 2H), 7.06 (d, 2H), 7.3-7.4 (m, 5H)
IR (KBr): 1741, 1695, 1662 cm⁻¹

Preparation 45

Boc-MeLeu-D-p-PyrPhLac-MeLeu-D-Lac-OBzl (0.76g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-p-PyrPhLac-MeLeu-D-Lac-OH (0.65g) was obtained according to a similar manner to that of preparation 25.

IR (KBr): 1740, 1695, 1664 cm⁻¹

Preparation 46

Boc-MeLeu-D-p-PyrPhLac-MeLeu-D-Lac-OBzl (0.76g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl. Except above matter, 2HCl•H-MeLeu-D-p-PyrPhLac-MeLeu-D-Lac-OBzl (0.77g) was obtained according to a similar manner to that of Preparation 28.

IR (KBr): 1743, 1646 cm⁻¹

Preparation 47

Boc-MeLeu-D-p-PyrPhLac-MeLeu-D-Lac-OH (0.65g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH, 2HCl•H-MeLeu-D-p-PyrPhLac-MeLeu-D-Lac-OBzl (0.76g) was used instead of HCl•H-MeLeu-D-Lac-OBzl. Except above matter, Boc-MeLeu-D-p-PyrPhLac-MeLeu-D-Lac-MeLeu-D-p-PyrphLac-MeLeu-D-Lac-OBzl (0.82g) was obtained according to a similar manner to that of Preparation 26.

NMR (CDCl₃, δ) 0.75-1.05 (m, 24H), 1.1-1.75 (m, 27H), 1.9-2.1 (m, 8H), 2.65-3.1 (m, 28H), 3.1-3.3 (m, 8H), 4.6-4.8 (m) and 4.9-5.5 (m) (10H), 6.35-6.55 (m, 4H), 7.0-7.2 (m, 4H), 7.3-7.4 (m, 5H)

IR (KBr): 1740, 1695, 1664 cm⁻¹

FAB-MS: 1295 [M + H]⁺

Preparation 48

Boc-MeLeu-D-p-PyrphLac-MeLeu-D-Lac-MeLeu-D-p-PyrPhLac-MeLeu-D-Lac-OBzl (0.80g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-p-PyrPhLac-MeLeu-D-Lac-MeLeu-D-p-PyrPhLac-MeLeu-D-Lac-OH (0.74g) was obtained according to a similar manner to that of Preparation 25.

IR (KBr): 1740, 1695, 1664 cm⁻¹

Preparation 49

Boc-MeLeu-D-p-PyrPhLac-MeLeu-D-Lac-MeLeu-D-p-PyrPhLac-MeLeu-D-Lac-OH (0.74g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl. Except above matter, 3HCl•H-MeLeu-D-p-PyrPhLac-MeLeu-D-Lac-MeLeu-D-p-PyrPhLac-MeLeu-D-Lac-OH (0.81g) was obtained according to a similar manner to that of Preparation 28.

IR (KBr): 1741,1647cm⁻¹

Preparation 50

1,4-dibromobutane (0.56ml) was used instead of 1,5-dibromopentane. Except above matter, benzyl (R)-2-hydroxy-3-(4-piperidinophenyl)propionate (1.05g). was obtained according to a similar manner to that of Preparation 41.

NMR (CDCl₃, δ) :1.50-1.80 (m,6H),2.65 (d,1H),2.90 (dd,1H),3.05 (dd,1H),3.05-3.2 (m,4H),4.44 (ddd,1H),5.17 (s,2H),6.82 (d,2H),7.01 (d,2H), 7.3-7.4 (m,5H)

IR (neat): 1720cm⁻¹

Preparation 51

H-D-p-PipPhLac-OBzl (0.79g) was used instead of H-D-p-Me₂NPhLac-OBzl. Except above matter Boc-MeLeu-D-p-PipPhLac-MeLeu-D-Lac-OBzl (1.71g) was obtained according to a similar manner to that of Preparation 24.

NMR (CDCl₃, δ) :0.90 (d,6H),1.4-1.8 (m,18H),2.62 (s) and 2.66 (s) (3H),3.0-3.15 (m,6H),4.65-4.15 (m) and 4.95-5.25 (m) (4H),6.82 (d,2H),7.03 (d,2H),7.2-7.35 (m,5H)

IR (KBr):1741,1695cm⁻¹

Preparation 52

Boc-MeLeu-D-p-PipPhLac-OBzl (1.68g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-p-PipPhLac-OH (1.38g) was obtained according to a similar manner to that of Preparation 25.

IR (KBr):1740,1694cm⁻¹

Preparation 53

Boc-MeLeu-D-p-PipPhLac-OH (1.38g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH. Except above matter, Boc-MeLeu-D-p-pipPhLac-MeLeu-D-Lac-OBzl (2.01g) was obtained according to a similar manner to that of Preparation 26.

NMR (CDCl₃, δ) :0.8-0.95 (m,12H),1.3-1.75 (m,24H),2.7-3.15 (m,12H),4.65-4.75 (m) and 4.9-6.4 (m,6H),6.84 (d,2H),7.09 (d,2H),7.3-7.4 (m,5H)

IR (KBr):1740,1695,1664cm⁻¹

Preparation 54

Boc-MeLeu-D-p-PipPhLac-MeLeu-D-Lac-OBzl (0.99g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-p-PipPhLac-MeLeu-D-Lac-OH (0.84g) was obtained according to a similar manner to that of Preparation 25.

IR (KBr):1740,1695,1665cm⁻¹

Preparation 55

Boc-MeLeu-D-p-PipPhLac-MeLeu-D-Lac-OBzl (0.98g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl. Except above matter, 2HCl•H-MeLeu-D-p-PipPhLac-MeLeu-D-Lac-OBzl (1.06g) was obtained according to a similar manner to that of Preparation 28.

IR (KBr):1744,1649cm⁻¹

Preparation 56

Boc-MeLeu-D-p-PipPhLac-MeLeu-D-Lac-OH (0.84g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH, 2HCl•H-MeLeu-D-p-PipPhLac-MeLeu-D-Lac-OBzl (1.06g) was used instead of HCl•H-MeLeu-D-Lac-OBzl. Except above matter, Boc-MeLeu-D-p-PipPhLac-MeLeu-D-Lac-MeLeu-D-p-PipPhLac-MeLeu-D-Lac-OBzl (1.18g) was obtained according to a similar manner to that of Preparation 26.

NMR (CDCl₃, δ): 0.75-1.0 (m, 24H), 1.05-1.8 (m, 39H), 2.65-3.2 (m, 24H), 4.65-4.75 (m) and 4.9-5.5 (m) (10H), 6.8-6.9 (m, 4H), 7.0-7.15 (m, 4H), 7.3-7.4 (m, 5H)

IR (KBr): 1738, 1694, 1663 cm⁻¹

FAB-MS: 1323 [M + H]⁺

Preparation 57

Boc-MeLeu-D-p-PipPhLac-MeLeu-D-Lac-MeLeu-D-p-PipPhLac-MeLeu-D-Lac-OBzl (1.17g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-p-PipPhLac-MeLeu-D-Lac-MeLeu-D-p-PipPhLac-MeLeu-D-Lac-OH (1.11g) was obtained according to a similar manner to that of Preparation 25.

IR (KBr): 1739, 1693, 1662 cm⁻¹

Preparation 58

Boc-MeLeu-D-p-PipPhLac-MeLeu-D-Lac-MeLeu-D-p-PipPhLac-MeLeu-D-Lac-OH (1.10g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl. Except above matter 3HCl•H-MeLeu-D-p-PipPhLac-MeLeu-D-Lac-MeLeu-D-p-PipPhLac-MeLeu-D-Lac-OH (1.24g) was obtained according to a similar manner to that of Preparation 28.

IR (KBr): 1742, 1652 cm⁻¹

Preparation 59

Under nitrogen atmosphere, to a suspended solution of anhydrous tetrahydrofuran (1ml) and metal magnesium (0.3g) was added dropwise a solution of 4-(2-methoxyethoxy)bromobenzene (2.9g) in anhydrous tetrahydrofuran (15ml) at room temperature. After the dropping, the solution was heated under reflux at 100 °C for 15 minutes, and then the residue was cooled down to -10 °C, added to cuprous bromide•dimethylsulfide complex (1.29g), and stirred for 30 minutes at -5 °C~3 °C. Further, it was cooled down to -60 °C, and the solution (5ml) of benzyl (R)-2,3-epoxypropionate (0.74g) in anhydrous tetrahydrofuran was added dropwise for 30 minutes and stirred for 1 and 1/2 hour successively. To the solution were added saturated aqueous ammonium chloride (10ml), and water (50ml), and was extracted with ethyl acetate (100ml × 2). After washing the ethyl acetate layer with saturated brine, the solution was dried over sodium sulfate and evaporated in vacuo. The solvent was evaporated in vacuo, the resultant crude product was purified by silica gel chromatography, and eluted with mixture of ethyl acetate and hexane (1:3, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain benzyl (R)-4-(2-methoxyethoxy) phenyl lactic acid (1.09g).

NMR (CDCl₃, δ): 2.92 (dd, 1H), 3.06 (dd, 1H), 3.47 (s, 3H), 3.74 (t, 2H), 4.08 (t, 2H), 4.45 (dd, 1H), 5.17 (s, 2H), 6.8 (d, 2H), 7.0 (d, 2H), 7.29-7.48 (m, 5H)

Preparation 60

H-D-p-MEPhLac-OBzl (0.92g) was used instead of H-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-p-MEPhLac-MeLeu-D-Lac-OBzl (1.15g) was obtained according to a similar manner to that of Preparation 24.

NMR (CDCl₃, δ): 0.90 (d, 6H), 1.4-1.65 (m, 12H), 2.6-2.7 (m, 3H), 3.01-3.12 (m, 2H), 3.45 (s, 3H), 3.67-3.78 (m, 2H), 4.02-4.12 (m, 2H), 4.62-5.22 (m, 4H), 6.77-6.86 (m, 2H), 7.02-7.12 (m, 2H), 7.22-7.4 (m, 5H)

FAB-MS: 458 [M-Boc + H]⁺

Preparation 61

Boc-MeLeu-D-p-MEPhLac-OBzl (1.5g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter Boc-MeLeu-D-p-MEPhLac-OH (1.29g) was obtained according to a similar manner to that of

Preparation 25.

NMR (CDCl₃, δ) :0.82-1.03 (m,6H),1.38-1.8 (m,12H),2.7-2.9 (m,3H), 3.03-3.3 (m,2H),3.45 (s,3H),3.65-3.78 (m,2H),4.05-4.17 (m,2H),4.4-4.51 (m) and 4.63-4.77 (m) (1H),5.2-5.38 (m,1H),6.85 (d,2H),7.13 (d,2H)

5 Preparation 62

Boc-MeLeu-D-p-MEPHLac-OH (1.29g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH. Except above matter Boc-MeLeu-D-p-MEPHLac-MeLeu-D-Lac-OBzl (1.87g) was obtained according to a similar manner to that of Preparation 26.

10 NMR(CDCl₃,δ) :0.80-0.95 (m,12H),1.4-1.7 (m,18H),2.79-2.97 (m,6H),3.01-3.09 (m,2H),3.45 (s,3H),3.64-3.79 (m,2H),4.02-4.17 (m,2H), 4.6-4.8 (m) and 4.9-5.43 (m) (6H),6.85 (d,2H),7.07-7.19 (m,2H), 7.3-7.42 (m,5H)
FAB-MS:657 [M-Boc + H]⁺

Preparation 63

15

Boc-MeLeu-D-p-MEPHLac-MeLeu-D-Lac-OBzl (0.85g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-p-MEPHLac-MeLeu-D-Lac-OH (0.67g) was obtained according to a similar manner to that of Preparation 25.

20 NMR (CDCl₃, δ) :0.80-0.99 (m,12H),1.4-1.7 (m,18H),2.76-2.95 (m,6H),3.0-3.19 (m,2H),3.45 (s,3H),3.74-3.8 (m,2H),4.04-4.18 (m,2H), 4.65-4.9 (m) and 5.12-5.39 (m) (4H),6.83 (d,2H),7.15 (d,2H)

Preparation 64

25 Boc-MeLeu-D-p-MEPHLac-MeLeu-D-Lac-OBzl (0.86g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl. Except above matter HCl•H-MeLeu-D-p-MEPHLac-MeLeu-D-Lac-OBzl (0.86g) was obtained according to a similar manner to that of Preparation 28.

NMR (CDCl₃, δ) :0.79-1.03 (m,12H),1.21-2.18 (m,9H),2.56-2.72 (m,3H),2.83-2.99 (m,3H),2.99-3.12 (m,2H),3.45 (s,3H),3.63-3.8 (m,3H), 4.03-4.17 (m,2H),5.03-5.58 (m,5H),6.86 (d,2H),7.07-7.43 (m,7H)

30 Preparation 65

Boc-MeLeu-D-p-MEPHLac-MeLeu-D-Lac-OH (0.66g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH, HCl•H-MeLeu-D-p-MEPHLac-MeLeu-D-Lac-OBzl (0.84g) was used instead of HCl•H-MeLeu-D-Lac-OBzl. Except above matter Boc-MeLeu-D-p-MEPHLac-MeLeu-D-Lac-MeLeu-D-p-MEPHLac-MeLeu-D-Lac-OBzl (1.24g) was obtained according to a similar manner to that of Preparation 26.

35 NMR (CDCl₃, δ) :0.77-1.0 (m,24H),1.15-1.79 (m,27H),2.7-3.17 (m,16H),3.45 (s,6H),3.66-3.78 (m,4H),4.02-4.14 (m,4H),4.6-4.78 (m) and 4.9-5.5 (m) (10H),6.78-6.95 (m,4H),7.03-7.18 (m,4H),7.3-7.42 (m,5H)
FAB-MS:1205 [M-Boc + H]⁺

40 Preparation 66

Boc-MeLeu-D-p-MEPHLac-MeLeu-D-Lac-MeLeu-D-p-MEPHLac-MeLeu-D-Lac-OBzl (1.22g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter Boc-MeLeu-D-p-MEPHLac-MeLeu-D-Lac-MeLeu-D-p-MEPHLac-MeLeu-D-Lac-OH (1.03g) was obtained according to a similar manner to that of Preparation 25.

45 NMR (CDCl₃, δ) :0.77-1.02 (m,24H),1.18-1.8 (m,27H),2.7-3.09 (m,16H),3.45 (s,6H),3.65-3.8 (m,4H),3.98-4.17 (m,4H),4.58-5.77 (m,8H), 6.84 (d,4H),7.14 (d,4H)

Preparation 67

50

Under nitrogen atmosphere, at -15 °C, to dichloromethane solution of (R)-isopropylidene glycerol (2g) and triethylamine (5.05ml) was added dropwise dichloromethane solution of trifluoromethanesulfonic anhydride (3.05ml). After stirring for half an hour successively, dichloromethane was added and the mixture was washed with water, saturated aqueous sodium bicarbonate, saturated brine and dried over anhydrous sodium sulfate and filtrated with silica gel. The solvent was evaporated in vacuo and azeotroped by toluene to gain the crude product of triflate. To tetrahydrofuran solution of magnesium (0.61g) was added dropwise tetrahydrofuran solution of 2-bromoanisole (2.82ml), and for half an hour it was heated under reflux. Under ice-cooling, the copper bromide dimethylsulfide complex (0.99g) was then added. Further tetrahydrofuran

solution of the above crude product of triflate was added dropwise and stirred for 2 hours successively, aqueous ammonium chloride was added, and was extracted with ethyl acetate. The extract was dried magnesium over sodium sulfate. The solvent was evaporated in vacuo, the resultant crude product was purified by silica gel column chromatography, and eluted with mixture of ethyl acetate and hexane (4:1, v/v).

5 The fractions containing the desired product were combined and evaporated in vacuo to obtain (R)-4-(2-methoxybenzyl)-2,2-dimethyl-1,3-dioxolane (2.25g).

NMR (CDCl₃, δ) :1.35 (s,3H),1.44 (s,3H),2.81 (dd,1H),3.02 (dd,1H),3.66 (dd,1H),3.81 (s,3H),3.88 (dd,1H),4.37 (dt,1H),6.79-6.93 (m,2H), 7.13-7.25 (m,2H)

10 Preparation 68

(R)-4-(2-methoxybenzyl)-2,2-dimethyl-1,3-dioxolane (2.2g) was dissolved in ethanol (20ml) and to 6N-aqueous hydrochloric acid solution was added and stirred for 2 hours at room temperature. After evaporating ethanol in vacuo, water was added and extracted with ethyl acetate. After washing with aqueous

15 saturated sodium bicarbonate solution, it was dried over sodium sulfate and evaporated in vacuo to give (R)-3-(2-methoxyphenyl)propane-1,2-diol (1.62g).

NMR (CDCl₃, δ) :2.75-2.93 (m,2H),3.40-4.00 (m,3H),3.85 (s,3H), 6.82-6.97 (m,2H),7.12-7.28 (m,2H)

Preparation 69

20 Under ice-cooling, to a solution of (R)-3-(2-methoxyphenyl)propane-1,2-diol (1.62g) and imidazole (0.92g) in dimethylformamide was added t-butyldimethylsilylchloride (1.36g), and stirred for 15 minutes successively. The reaction solution was poured into water, extracted with ethyl acetate, and dried over sodium sulfate. After the solvent was evaporated in vacuo, the gained crude product was purified by silica

25 gel column chromatography, and it was eluted with a mixed solvent of hexane and ethyl acetate (7:1, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain (R)-1-t-butyldimethylsiloxy-3-(2-methoxyphenyl)-2-propanol (2.22g).

NMR (CDCl₃, δ) :0.063 (s,6H),0.91 (s,9H),2.59 (d,1H),2.78-2.84 (m,2H), 3.45-3.68 (m,2H),3.88 (s,3H),3.89-3.97 (m,1H),6.83-6.94 (m,2H), 7.16-7.26 (m,2H)

30 Preparation 70

Under ice-cooling, to a dichloromethane solution of (R)-1-t-butyldimethylsiloxy-3-(2-methoxyphenyl)-2-propanol (2.2g) were added diisopropylethylamine (2.59ml) and methoxymethylchloride (0.85ml) and

35 stirred at room temperature for 18 hours. After evaporating dichloromethane in vacuo, water was added, extracted with ethyl acetate, and dried over magnesium sulfate. The solvent was evaporated in vacuo and the resultant crude product was purified by silica gel column chromatography, and it was eluted with a mixed solvent of hexane and ethyl acetate (6:1, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain (R)-1-t-butyldimethylsiloxy-2-methoxymethoxy-3-(2-methoxyphenyl)propane (2.22g).

NMR (CDCl₃, δ) :0.04 (s,6H),0.89 (s,9H),2.68 (dd,1H),2.91 (dd,1H),3.15 (s,3H),3.63 (d,2H),3.79 (s,3H),3.82-3.99 (m,1H),4.52 (d,1H),4.67 (d,1H), 6.80-6.91 (m,2H),7.11-7.26 (m,2H)

Preparation 71

45 Under ice-cooling, to a tetrahydrofuran solution of (R)-1-t-butyldimethylsiloxy-2-methoxymethoxy-3-(2-methoxyphenyl)propane (2.2g) was added a solution of n-tetrabutylammoniumfluoride (1mol/1.6.46ml) in tetrahydrofuran and stirred for 2 hours successively. After tetrahydrofuran was evaporated in vacuo, water was added, extracted with ethyl acetate, and dried over magnesium sulfate. The solvent was evaporated in

50 vacuo, the gained crude product was purified by silica gel column chromatography, and eluted with a mixed solvent of hexane and ethyl acetate (1:1, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain (R)-2-methoxymethoxy-3-(2-methoxyphenyl)-1-propanol (1.51g).

NMR (CDCl₃, δ) :2.85 (d,2H),3.36 (s,3H),3.41-3.70 (m,2H),3.83 (s,3H), 3.82-3.98 (m,1H),4.62 (d,1H),4.68 (d,1H),6.83-6.92 (m,2H),7.12-7.26 (m,2H)

Preparation 72

To dimethylformamide solution (17.5ml) of (R)-2-methoxymethoxy-3-(2-methoxyphenyl)-1-propanol (1.5g) was added pyridinium dichromate (8.73g) and stirred for 15 hours at room temperature. To the reaction solution was added silica gel and ethyl acetate. The mixture was filtered through silica gel. The solvent was evaporated in vacuo, ethyl acetate-benzene (1:1) was added, washed with water and dried over magnesium sulfate. After the solvent was evaporated in vacuo, tetrahydrofuran (6ml), 6N-aqueous hydrochloric acid (6ml) was added and stirred for 2 hours at 50 °C. After tetrahydrofuran was evaporated in vacuo, water was added, extracted with ethyl acetate, washed with water, and dried over magnesium sulfate. After the solvent was evaporated in vacuo, dimethylformamide, potassium carbonate (0.7g) was added and under ice-cooling, benzyl bromide was added dropwise. After the mixture was stirred for 1 and 1/2 hour, water was added, extracted with ethyl acetate, and dried over magnesium sulfate. The solvent was evaporated in vacuo, the resultant crude product was purified by silica gel column chromatography, and eluted with mixture of hexane and ethyl acetate (3:1, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain benzyl (R)-2-hydroxy-3-(2-methoxyphenyl)propionate (1.02g).
 NMR (CDCl₃, δ) :2.92 (d,1H),3.03 (dd,1H),3.18 (dd,1H),3.83 (s,3H), 4.46-4.58 (m,1H),5.11 (d,1H),5.19 (d,1H)-6.83-6.91 (m,2H),7.18-7.38 (m,7H)
 EI-MS:286 [M]⁺

Preparation 73

H-D-o-MeOPhLac-OBzl (1g) was used instead of H-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-o-MeOPhLac-OBzl (1.73g) was obtained according to a similar manner to that of Preparation 24.
 NMR (CDCl₃, δ) :0.88 (d,6H),1.18-1.65 (m,12H),2.58-2.78 (m,3H), 2.98-3.38 (m,2H),3.79 (s,3H),4.66-5.00 (m,1H),5.08-5.18 (m,2H), 5.20-5.40 (m,1H),6.76-6.89 (m,2H),7.07-7.40 (m,7H)

Preparation 74

Boc-MeLeu-D-o-MeOPhLac-OBzl (1.7g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-o-MeOPhLac-OH (1.54g) was obtained according to a similar manner to that of Preparation 25.
 NMR (CDCl₃, δ) :0.80-0.95 (m,6H),1.20-1.62 (m,12H),2.69-2.74 (m,3H),3.02 (dd,1H),3.31-3.43 (m,1H),3.82 (s,3H),4.51-4.72 (m,1H), 5.25-5.43 (m,1H),6.80-6.92 (m,2H),7.11-7.26 (m,2H)

Preparation 75

Boc-MeLeu-D-o-MeOPhLac-OH (1.5g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH. Except above matter, Boc-MeLeu-D-o-MeOPhLac-MeLeu-D-Lac-OBzl (2.09g) was obtained according to a similar manner to that of Preparation 26.

NMR (CDCl₃, δ) :0.82-0.99 (m,12H),1.20-1.80 (m,18H),2.70-3.34 (m,8H),3.84 (s) and 3.79 (s) (3H),4.59-5.58 (m,6H),6.81-6.92 (m,2H), 7.13-7.35 (m,7H)

Preparation 76

Boc-MeLeu-D-o-MeOPhLac-MeLeu-D-Lac-OBzl (1g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-o-MeOPhLac-MeLeu-D-Lac-OH (0.98g) was obtained according to a similar manner to that of Preparation 25.

NMR (CDCl₃, δ) :0.82-1.01 (m,12H),1.10-1.78 (m,18H),2.69-3.21 (m,8H),3.86 (s,3H),4.62-5.92 (m,4H),6.81-6.92 (m,2H),7.12-7.26 (m,2H)

Preparation 77

Boc-MeLeu-D-o-MeOPhLac-MeLeu-D-Lac-OBzl (1g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl. Except above matter, HCl•H-MeLeu-D-o-MeOPhLac-MeLeu-D-Lac-OBzl (0.94g) was obtained according to a similar manner to that of Preparation 28.

NMR (CDCl₃, δ) :0.68-1.01 (m,12H),1.10-1.98 (m,9H),2.56-3.40 (m,8H),3.67-3.82 (m,1H),3.84 (s,3H),4.95-5.72 (m,5H),6.81-6.93 (m,2H), 7.15-7.36 (m,7H)

Preparation 78

Boc-MeLeu-D-o-MeOPhLac-MeLeu-D-Lac-OH (0.98g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH, and HCl•H-MeLeu-D-o-MeOPhLac-MeLeu-D-Lac-OBzl (0.94g) was used instead of HCl•H-MeLeu-D-Lac-OBzl. Except above matter, Boc-MeLeu-D-o-MeOPhLac-MeLeu-D-Lac-MeLeu-D-o-MeOPhLac-MeLeu-D-Lac-OBzl (1.26g) was obtained according to a similar manner to that of Preparation 26.
NMR (CDCl₃, δ) : 0.79-1.00 (m, 24H), 1.19-1.82 (m, 27H), 2.72-3.19 (m, 16H), 3.79-3.92 (m, 6H), 4.61-5.62 (m, 10H), 6.77-6.93 (m, 4H), 7.17-7.38 (m, 9H)

10 Preparation 79

Boc-MeLeu-D-o-MeOPhLac-MeLeu-D-Lac-MeLeu-D-o-MeOPhLac-MeLeu-D-Lac-OBzl (1.25g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-o-MeOPhLac-MeLeu-D-Lac-MeLeu-D-o-MeOPhLac-MeLeu-D-Lac-OH (1.24g) was obtained according to a similar manner to that of Preparation 25.
NMR (CDCl₃, δ) : 0.78-1.00 (m, 24H), 1.15-1.82 (m, 27H), 2.62-3.22 (m, 16H), 3.85 (s, 6H), 4.42-5.90 (m, 8H), 6.80-6.92 (m, 4H), 7.15-7.26 (m, 4H)

Preparation 80

20

3-bromoanisole (2.82ml) was used instead of 2-bromoanisole. Except above matter, (R)-4-(3-methoxybenzyl)-2,2-dimethyl-1,3-dioxolane (2.25g) was obtained according to a similar manner to that of Preparation 67.

NMR (CDCl₃, δ) : 1.36 (s, 3H), 1.44 (s, 3H), 2.73 (dd, 1H), 3.00 (dd, 1H), 3.61 (dd, 1H), 3.79 (s, 3H), 3.97 (dd, 1H), 4.32 (dt, 1H), 6.76-6.82 (m, 3H), 7.17-7.23 (m, 1H)

Preparation 81

(R)-4-(3-methoxybenzyl)-2,2-dimethyl-1,3-dioxolane (1.3g) was used instead of (R)-4-(2-methoxybenzyl)-2,2-dimethyl-1,3-dioxolane. Except above matter, (R)-3-(3-methoxyphenyl)propane-1,2-diol (1g) was obtained according to a similar manner to that of Preparation 68.

NMR (CDCl₃, δ) : 1.93 (t, 1H), 2.06 (d, 1H), 2.67-2.82 (m, 2H), 3.47-3.79 (m, 2H), 3.81 (s, 3H), 3.90-4.02 (m, 1H), 6.77-6.84 (m, 3H), 7.20-7.28 (m, 1H)

35 Preparation 82

(R)-3-(3-methoxyphenyl)propane-1,2-diol (0.99g) was used instead of (R)-3-(2-methoxyphenyl)propane-1,2-diol. Except above matter, (R)-1-t-butyldimethylsiloxy-3-(3-methoxyphenyl)-2-propanol (1.4g) was obtained according to a similar manner to that of Preparation 69.

NMR (CDCl₃, δ) : 0.065 (s, 6H), 0.91 (s, 9H), 2.40 (d, 1H), 2.75 (d, 2H), 3.45 (dd, 1H), 3.61 (dd, 1H), 3.79 (s, 3H), 3.85-4.00 (m, 1H), 6.75-6.83 (m, 3H), 7.17-7.26 (m, 1H)

Preparation 83

(R)-1-t-butyldimethylsiloxy-3-(3-methoxyphenyl)-2-propanol (1.4g) was used instead of (R)-1-t-butyldimethylsiloxy-3-(2-methoxyphenyl)-2-propanol. Except above matter (R)-1-t-butyldimethylsiloxy-2-methoxymethoxy-3-(3-methoxyphenyl)propane (1.5g) was obtained according to a similar manner to that of Preparation 70.

NMR (CDCl₃, δ) : 0.07 (s, 6H), 0.91 (s, 9H), 2.71 (dd, 1H), 2.89 (dd, 1H), 3.16 (s, 3H), 3.53-3.68 (m, 2H), 3.80 (s, 3H), 3.79-3.90 (m, 1H), 4.51 (d, 1H), 4.68 (d, 1H), 6.72-6.85 (m, 3H), 7.11-7.20 (m, 1H)

Preparation 84

(R)-1-t-butyldimethylsiloxy-2-methoxymethoxy-3-(3-methoxyphenyl)propane (1.5g) was used instead of (R)-1-t-butyldimethylsiloxy-2-methoxymethoxy-3-(2-methoxyphenyl)propane. Except above matter, (R)-2-methoxymethoxy-3-(3-methoxyphenyl)-1-propanol (0.93g) was obtained according to a similar manner to that of Preparation 71.

NMR (CDCl₃, δ) : 2.69-2.92 (m, 2H), 3.35 (s, 3H), 3.45-3.68 (m, 2H), 3.79 (s, 3H), 3.70-3.86 (m, 1H), 4.57 (d, 1H), 4.68

(d,1H),6.73-6.83 (m,3H), 7.16-7.26 (m,1H)

Preparation 85

5 (R)-2-methoxymethoxy-3-(3-methoxyphenyl)-1-propanol (0.93g) was used instead of (R)-2-methoxymethoxy-3-(2-methoxyphenyl)-1-propanol. Except above matter, benzyl (R)-2-hydroxy-3-(3-methoxyphenyl)propionate (0.61g) was obtained according to a similar manner to that of Preparation 72.
NMR (CDCl₃,δ) :2.72 (d,1H),2.95 (dd,1H),3.10 (dd,1H),3.77 (s,3H), 4.41-4.55 (m,1H),5.18 (s,2H),6.71-6.80 (m,3H),7.13-7.39 (m,6H)

Preparation 86

15 H-D-m-MeOPhLac-OBzl (0.6g) was used instead of H-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-m-MeOPhLac-OBzl (1.06g) was obtained according to a similar manner to that of Preparation 24.
NMR (CDCl₃,δ) :0.89 (d,6H),1.26-1.57 (m,12H),2.62-2.75 (m,3H), 3.02-3.22 (m,2H),3.76 (s,3H),4.62-5.30 (m,4H),6.73-6.79 (m,3H), 7.14-7.34 (m,6H)

Preparation 87

20 Boc-MeLeu-D-m-MeOPhLac-OBzl (1g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-m-MeOPhLac-OH (0.93g) was obtained according to a similar manner to that of Preparation 25.
NMR (CDCl₃,δ) :0.82-0.98 (m,6H),1.30-1.80 (m,12H),2.64-2.80 (m,3H),3.03-3.32 (m,2H),3.79 (s,3H),4.42-5.40 (m,2H),6.76-6.84 (m,3H), 7.16-7.26 (m,1H)

Preparation 88

30 Boc-MeLeu-D-m-MeOPhLac-OH (0.93g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH. Except above matter, Boc-MeLeu-D-m-MeOPhLac-MeLeu-D-Lac-OBzl (1.28g) was obtained according to a similar manner to that of Preparation 26.
NMR (CDCl₃,δ) :0.82-0.99 (m,12H),1.20-1.75 (m,18H),2.75-2.92 (m,6H),3.00-3.20 (m,2H),3.78 (s,3H),4.62-5.50 (m,6H),6.76-6.84 (m,3H), 7.17-7.39 (m,6H)

Preparation 89

35 Boc-MeLeu-D-m-MeOPhLac-MeLeu-D-Lac-OBzl (0.64g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-m-MeOPhLac-MeLeu-D-Lac-OH (0.6g) was obtained according to a similar manner to that of Preparation 25.
NMR (CDCl₃,δ) :0.80-0.98 (m,12H),1.10-1.75 (m,18H),2.73-3.22 (m,8H),3.78 (s,3H),4.60-5.85 (m,4H),6.75-6.85 (m,3H),7.18-7.25 (m,1H)

Preparation 90

45 Boc-MeLeu-D-m-MeOPhLac-MeLeu-D-Lac-OBzl (0.61g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl. Except above matter, HCl•H-MeLeu-D-m-MeOPhLac-MeLeu-D-Lac-OBzl (0.6g) was obtained according to a similar manner to that of Preparation 28.
NMR (CDCl₃,δ) :0.62-1.00 (m,12H),1.10-1.98 (m,9H),2.56-3.10 (m,8H),3.70-3.82 (m,1H),3.79 (s,3H),5.02-5.59 (m,5H),6.75-6.90 (m,3H), 7.15-7.40 (m,6H)

Preparation 91

55 Boc-MeLeu-D-m-MeOPhLac-MeLeu-D-Lac-OH (0.6g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH and HCl•H-MeLeu-D-m-MeOPhLac-MeLeu-D-Lac-OBzl (0.6g) was used instead of HCl•H-MeLeu-D-Lac-OBzl. Except above matter, Boc-MeLeu-D-m-MeOPhLac-MeLeu-D-Lac-MeLeu-D-m-MeOPhLac-MeLeu-D-Lac-OBzl (0.82g) was obtained according to a similar manner to that of Preparation 26.
NMR (CDCl₃,δ) :0.70-1.02 (m,24H),1.20-1.79 (m,27H),2.70-3.19 (m,16H),3.78 (s,6H),5.01-5.60 (m,10H),6.70-6.92 (m,6H),7.18-7.34 (m,7H)

Preparation 92

Boc-MeLeu-D-m-MeOPhLac-MeLeu-D-Lac-MeLeu-D-m-MeOPhLac-MeLeu-D-Lac-OBzl (0.82g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-m-MeOPhLac-MeLeu-D-Lac-MeLeu-D-m-MeOPhLac-MeLeu-D-Lac-OH (0.79g) was obtained according to a similar manner to that of Preparation 25.

NMR (CDCl₃, δ) : 0.75-1.00 (m, 24H), 1.10-1.80 (m, 27H), 2.60-3.19 (m, 16H), 3.78 (s, 6H), 4.58-5.78 (m, 8H), 6.71-6.90 (m, 6H), 7.12-7.35 (m, 2H)

Preparation 93

1-bromo-3,4-dimethoxybenzene (1.83g) was used instead of 4-(2-methoxyethoxy)bromobenzene. Except above matter, benzyl (R)-2-hydroxy-3-(3,4-dimethoxyphenyl)propionate (0.23g) was obtained according to a similar manner to that of Preparation 59.

NMR (CDCl₃, δ) : 2.71 (d, 1H), 2.93 (dd, 1H), 3.08 (dd, 1H), 3.79 (s, 3H), 3.85 (s, 3H), 4.42-4.55 (m, 1H), 5.19 (s, 2H), 6.65-6.76 (m, 3H), 7.26-7.40 (m, 5H)

Preparation 94

H-D-3,4-DMOPhLac-OBzl (0.23g) was used instead of H-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-3,4-DMOPhLac-OBzl (0.34g) was obtained according to a similar manner to that of Preparation 24.

NMR (CDCl₃, δ) : 0.89 (d, 6H), 1.39-1.62 (m, 12H), 2.62-2.73 (m, 3H), 3.01-3.19 (m, 2H), 3.82 (s, 3H), 3.85 (s, 3H), 4.62-5.32 (m, 4H), 6.65-6.80 (m, 3H), 7.20-7.40 (m, 5H)

Preparation 95

Boc-MeLeu-D-3,4-DMOPhLac-OBzl (0.34g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-3,4-DMOPhLac-OH (0.3g) was obtained according to a similar manner to that of Preparation 25.

NMR (CDCl₃, δ) : 0.85-0.96 (m, 6H), 1.42 (s, 9H), 1.22-1.69 (m, 3H), 2.73-2.82 (m, 3H), 2.95-3.22 (m, 2H), 3.85 (s, 3H), 3.87 (s, 3H), 4.38-4.70 (m, 1H), 5.21-5.39 (m, 1H), 6.72-6.83 (m, 3H)

Preparation 96

Boc-MeLeu-D-3,4-DMOPhLac-OH (0.3g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH. Except above matter, Boc-MeLeu-D-3,4-DMOPhLac-MeLeu-D-Lac-OBzl (0.41g) was obtained according to a similar manner to that of Preparation 26.

NMR (CDCl₃, δ) : 0.82-0.98 (m, 12H), 1.35-1.69 (m, 18H), 2.77-3.15 (m, 8H), 3.85 (s, 3H), 3.87 (s, 3H), 4.62-5.48 (m, 6H), 6.72-6.80 (m, 3H), 7.26-7.39 (m, 5H)

Preparation 97

Boc-MeLeu-D-3,4-DMOPhLac-MeLeu-D-Lac-OBzl (0.2g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-3,4-DMOPhLac-MeLeu-D-Lac-OH (0.2g) was obtained according to a similar manner to that of Preparation 25.

NMR (CDCl₃, δ) : 0.79-1.00 (m, 12H), 1.24-1.80 (m, 18H), 2.74-3.16 (m, 8H), 3.85 (s, 3H), 3.87 (s, 3H), 4.59-5.78 (m, 4H), 6.77 (s, 3H)

Preparation 98

Boc-MeLeu-D-3,4-DMOPhLac-MeLeu-D-Lac-OBzl (0.2g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl. Except above matter, HCl·H-MeLeu-D-3,4-DMOPhLac-MeLeu-D-Lac-OBzl (0.18g) was obtained according to a similar manner to that of Preparation 28.

NMR (CDCl₃, δ) : 0.78-0.98 (m, 12H), 1.20-2.00 (m, 9H), 2.62-3.15 (m, 8H), 3.69-3.82 (m, 1H), 3.85 (s, 3H), 3.87 (s, 3H), 5.02-5.60 (m, 5H), 6.74-6.82 (m, 3H), 7.22-7.38 (m, 5H)

Preparation 99

Boc-MeLeu-D-3,4-DMOPhLac-MeLeu-D-Lac-OH (0.2g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH, and HCl•H-MeLeu-D-3,4-DMOPhLac-MeLeu-D-Lac-OBzl (0.18g) was used instead of HCl•H-MeLeu-D-Lac-OBzl. Except above matter, Boc-MeLeu-D-3,4-DMOPhLac-MeLeu-D-Lac-MeLeu-D-3,4-DMOPhLac-MeLeu-D-Lac-OBzl (0.27g) was obtained according to a similar manner to that of Preparation 26.

NMR (CDCl₃, δ) :0.70-1.00 (m,24H),1.20-1.79 (m,27H),2.72-3.18 (m,16H),3.84 (s,6H),3.86 (s,6H),4.62-5.48 (m,10H),6.72-6.83 (m,6H), 7.21-7.40 (m,5H)

Preparation 100

Boc-MeLeu-D-3,4-DMOPhLac-MeLeu-D-Lac-MeLeu-D-3,4-DMOPhLac-MeLeu-D-Lac-OBzl (0.26g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-3,4-DMOPhLac-MeLeu-D-Lac-MeLeu-D-3,4-DMOPhLac-MeLeu-D-Lac-OH (0.26g) was obtained according to a similar manner to that of Preparation 25.

NMR (CDCl₃, δ) :0.76-1.02 (m,24H),1.32-1.75 (m,27H),2.72-3.20 (m,16H),3.85 (s,6H),3.87 (s,6H),4.60-5.70 (m,8H),6.72-6.80 (m,6H)

Preparation 101

1-bromo-2,4-dimethoxybenzene (2.93g) was used instead of 4-(2-methoxyethoxy)bromobenzene. Except above matter, benzyl (R)-2-hydroxy-3-(2,4-dimethoxyphenyl)propionate (1.28g) was obtained according to a similar manner to that of Preparation 59.

NMR (CDCl₃, δ) :2.87 (d,1H),2.96 (dd,1H),3.10 (dd,1H),3.76 (s,3H),3.78 (s,3H),4.43-4.53 (m,1H),5.12 (d,1H),5.19 (d,1H),6.36-6.43 (m,2H),6.99 (d,1H),7.21-7.40 (m,5H)

Preparation 102

H-D-2,4-DMOPhLac-OBzl (1.27g) was used instead of H-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-2,4-DMOPhLac-OBzl (2.16g) was obtained according to a similar manner to that of Preparation 24.

NMR (CDCl₃, δ) :0.89 (d,6H),1.36-1.60 (m,12H),2.61-2.70 (m,3H), 2.92-3.29 (m,2H),3.76 (s,3H),3.77 (s,3H),4.60-5.35 (m,4H),6.31-6.40 (m,2H),6.97 (d,1H),7.19-7.40 (m,5H)

Preparation 103

Boc-MeLeu-D-2,4-DMOPhLac-OBzl (2.15g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-2,4-DMOPhLac-OH (1.61g) was obtained according to a similar manner to that of Preparation 25.

NMR (CDCl₃, δ) :0.82-0.93 (m,6H),1.38-1.62 (m,12H),2.73 (brs,3H), 2.91-3.39 (m,2H),3.78 (s,6H),4.58-4.70 (m,1H),5.20-5.39 (m,1H), 6.37-6.44 (m,2H),7.03 (d,1H)

Preparation 104

Boc-MeLeu-D-2,4-DMOPhLac-OH (1.6g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH. Except above matter, Boc-MeLeu-D-2,4-DMOPhLac-MeLeu-D-Lac-OBzl (2.2g) was obtained according to a similar manner to that of Preparation 26.

NMR (CDCl₃, δ) :0.80-1.05 (m,12H),1.32-1.65 (m,18H),2.75-3.15 (m,8H),3.78 (s,3H),3.81 (s,3H),4.60-5.60 (m,6H),6.30-6.46 (m,2H), 7.00-7.09 (m,1H),7.25-7.40 (m,5H)

Preparation 105

Boc-MeLeu-D-2,4-DMOPhLac-MeLeu-D-Lac-OBzl (1.1g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-2,4-DMOPhLac-MeLeu-D-Lac-OH (1g) was obtained according to a similar manner to that of Preparation 25.

NMR (CDCl₃, δ) :0.80-1.00 (m,12H),1.15-1.78 (m,18H),2.70-3.12 (m,8H),3.78 (s,3H),3.83 (s,3H),4.60-5.87 (m,4H),6.30-6.42 (m,2H),7.04 (d,1H)

Preparation 106

Boc-MeLeu-D-2,4-DMOPhLac-MeLeu-D-Lac-OBzl (1g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl. Except above matter, HCl•H-MeLeu-D-2,4-DMOPhLac-MeLeu-D-Lac-OBzl (0.98g) was obtained according to a similar manner to that of Preparation 28.

NMR (CDCl₃, δ) :0.69-1.02 (m,12H),1.20-2.00 (m,9H),2.58-3.20 (m,8H),3.70-3.80 (m,1H),3.78 (s,3H),3.81 (s,3H),5.00-5.71 (m,5H), 6.37-6.46 (m,2H),7.07 (d,1H),7.20-7.42 (m,5H)

Preparation 107

Boc-MeLeu-D-2,4-DMOPhLac-MeLeu-D-Lac-OH (1g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH, and HCl•H-MeLeu-D-2,4-DMOPhLac-MeLeu-D-Lac-OBzl (0.98g) was used instead of HCl•H-MeLeu-D-Lac-OBzl. Except above matter, Boc-MeLeu-D-2,4-DMOPhLac-MeLeu-D-Lac-MeLeu-D-2,4-DMOPhLac-MeLeu-D-Lac-OBzl (1.48g) was obtained according to a similar manner to that of Preparation 26.

NMR (CDCl₃, δ) :0.82-1.00 (m,24H),1.15-1.80 (m,27H),2.75-3.21 (m,16H),3.72-3.84 (m,12H),4.60-5.60 (m,10H),6.31-6.49 (m,4H), 7.00-7.17 (m,2H),7.21-7.40 (m,5H)

Preparation 108

Boc-MeLeu-D-2,4-DMOPhLac-MeLeu-D-Lac-MeLeu-D-2,4-DMOPhLac-MeLeu-D-Lac-OBzl (1.45g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-2,4-DMOPhLac-MeLeu-D-Lac-MeLeu-D-2,4-DMOPhLac-MeLeu-D-Lac-OH (1.49g) was obtained according to a similar manner to that of Preparation 25.

NMR (CDCl₃, δ) :0.80-1.02 (m,24H),1.20-1.90 (m,27H),2.71 - 3.22 (m,16H),3.81 (s) and 3.78 (s) (12H),4.60-5.80 (m,8H),6.33-6.46 (m,4H), 7.01-7.15 (m,2H)

Preparation 109

1-bromo-3,4-methylenedioxybenzene (2.05ml) was used instead of 2-bromoanisole. Except above matter, (R)-4-(3,4-methylenedioxybenzyl)-2,2-dimethyl-1,3-dioxolane (1.64g) was obtained according to a similar manner to that of Preparation 67.

NMR (CDCl₃, δ) :1.35 (s,3H),1.43 (s,3H),2.69 (dd,1H),2.91 (dd,1H),3.62 (dd,1H),3.97 (dd,1H),4.27 (dt,1H),5.93 (s,2H),6.58-6.78 (m,3H)

Preparation 110

(R)-2,2-dimethyl-5-(3,4-methylenedioxybenzyl)-1,3-dioxolane (1.63g) was used instead of (R)-2,2-dimethyl-5-(2-methoxybenzyl)-1,3-dioxolane. Except above matter, (R)-3-(3,4-methylenedioxyphenyl)-propane-1,2-diol (1.37g) was obtained according to a similar manner to that of Preparation 68.

NMR (CDCl₃, δ) :2.63 (dd,1H),2.72 (dd,1H),3.48 (dd,1H),3.67 (dd,1H), 3.80-3.96 (m,1H),5.92 (s,2H),6.58-6.78 (m,3H)

Preparation 111

(R)-3-(3,4-methylenedioxyphenyl)-propane-1,2-diol (1.25g) was used instead of (R)-3-(2-methoxyphenyl)-propane-1,2-diol. Except above matter, (R)-1-t-butyldimethylsiloxy-3-(3,4-methylenedioxyphenyl)-2-propanol (1.77g) was obtained according to a similar manner to that of Preparation 69.

NMR (CDCl₃, δ) :0.07 (s,6H),0.91 (s,9H),2.69 (d,2H),3.46 (dd,1H),3.61 (dd,1H),3.79-3.85 (m,1H),5.93 (s,2H),6.63-6.77 (m,3H)

Preparation 112

(R)-1-t-butyldimethylsiloxy-3-(3,4-methylenedioxyphenyl)-2-propanol (1.77g) was used instead of (R)-1-t-butyldimethylsiloxy-3-(2-methoxyphenyl)-2-propanol. Except above matter, (R)-1-t-butyldimethylsiloxy-2-methoxymethoxy-3-(3,4-methylenedioxyphenyl)propane (1.79g) was obtained according to a similar manner to that of Preparation 70.

NMR (CDCl₃, δ) :0.07 (s,6H),0.90 (s,9H),2.65 (dd,1H),2.83 (dd,1H),3.20 (s,3H),3.52-3.62 (m,2H),3.71-3.83 (m,1H),4.52 (d,1H),4.68 (d,1H),5.92 (s,2H),6.64-6.75 (m,3H)

Preparation 113

(R)-1-t-butylidimethylsiloxy-3-(3,4-methylenedioxyphenyl)-2-methoxymethoxypropane (1.77g) was used instead of (R)-1-t-butylidimethylsiloxy-3-(2-methoxyphenyl)-2-methoxymethoxypropane. Except above matter, (R)-2-methoxymethoxy-3-(3,4-methylenedioxyphenyl)-1-propanol (1.17g) was obtained according to a similar manner to that of Preparation 71.

NMR (CDCl₃, δ) :2.69 (dd, 1H), 2.79 (dd, 1H), 3.37 (s, 3H), 3.49 (dd, 1H), 3.63 (dd, 1H), 3.71-3.82 (m, 1H), 4.58 (d, 1H), 4.68 (d, 1H), 5.93 (s, 2H), 6.62-6.78 (m, 3H)

Preparation 114

(R)-2-methoxymethoxy-3-(3,4-methylenedioxyphenyl)-1-propanol (0.92g) was used instead of (R)-2-methoxymethoxy-3-(2-methoxyphenyl)-1-propanol. Except above matter, benzyl (R)-2-hydroxy-3-(3,4-methylenedioxyphenyl)propionate (0.33g) was obtained according to a similar manner to that of Preparation 72.

NMR (CDCl₃, δ) :2.72 (d, 1H), 2.88 (dd, 1H), 3.04 (dd, 1H), 4.38-4.55 (m, 1H), 5.19 (s, 2H), 5.92 (s, 2H), 6.53-6.70 (m, 3H), 7.25-7.40 (m, 5H)

Preparation 115

H-D-3,4-MODPhLac-OBzl (0.5g) was used instead of H-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-3,4-MODPhLac-OBzl (0.74g) was obtained according to a similar manner to that of Preparation 24.

NMR (CDCl₃, δ) :0.91 (d, 6H), 1.38-1.70 (m, 12H), 2.62-2.83 (m, 3H), 2.98-3.20 (m, 2H), 4.55-5.26 (m, 4H), 5.92 (s, 2H), 6.52-6.75 (m, 3H), 7.21-7.40 (m, 5H)

Preparation 116

Boc-MeLeu-D-3,4-MODPhLac-OBzl (0.73g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-3,4-MODPhLac-OH (0.63g) was obtained according to a similar manner to that of Preparation 25.

NMR (CDCl₃, δ) :0.80-1.00 (m, 6H), 1.20-1.80 (m, 12H), 2.63-2.93 (m, 3H), 2.95-3.25 (m, 2H), 4.43-4.90 (m, 1H), 5.09-5.36 (m, 1H), 5.93 (s, 2H), 6.60-6.82 (m, 3H)

Preparation 117

Boc-MeLeu-D-3,4-MODPhLac-OH (0.63g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH. Except above matter, Boc-MeLeu-D-3,4-MODPhLac-MeLeu-D-Lac-OBzl (0.85g) was obtained according to a similar manner to that of Preparation 26.

NMR (CDCl₃, δ) :0.80-1.00 (m, 12H), 1.20-1.82 (m, 18H), 2.69-3.06 (m, 8H), 4.60-5.60 (m, 6H), 5.88-5.97 (m, 2H), 6.68-6.80 (m, 3H), 7.26-7.40 (m, 5H)

Preparation 118

Boc-MeLeu-D-3,4-MODPhLac-MeLeu-D-Lac-OBzl (0.42g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-3,4-MODPhLac-MeLeu-D-Lac-OH (0.39g) was obtained according to a similar manner to that of Preparation 25.

NMR (CDCl₃, δ) :0.80-1.00 (m, 12H), 1.20-1.80 (m, 18H), 2.65-3.20 (m, 8H), 4.60-5.80 (m, 4H), 5.93 (s, 2H), 6.62-6.78 (m, 3H)

Preparation 119

Boc-MeLeu-D-3,4-MODPhLac-MeLeu-D-Lac-OBzl (0.43g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl. Except above matter, HCl·H-MeLeu-D-3,4-MODPhLac-MeLeu-D-Lac-OBzl (0.4g) was obtained according to a similar manner to that of Preparation 28.

NMR (CDCl₃, δ) :0.78-1.05 (m, 12H), 1.20-2.40 (m, 9H), 2.60-3.25 (m, 8H), 3.60-3.90 (m, 1H), 5.02-5.58 (m, 5H), 5.85-5.98 (m, 2H), 6.65-6.92 (m, 3H), 7.20-7.42 (m, 5H)

Preparation 120

Boc-MeLeu-D-3,4-MODPhLac-MeLeu-D-Lac-OH (0.39g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH, and HCl•H-MeLeu-D-3,4-MODPhLac-MeLeu-D-Lac-OBzl (0.4g) was used instead of HCl•H-MeLeu-D-Lac-OBz. Except above matter, Boc-MeLeu-D-3,4-MODPhLac-MeLeu-D-Lac-MeLeu-D-3,4-MODPhLac-MeLeu-D-Lac-OBzl (0.59g) was obtained according to a similar manner to that of Preparation 26.
 NMR (CDCl₃, δ) :0.75-1.05 (m,24H),1.15-1.90 (m,27H),2.62-3.15 (m,16H),4.60-5.60 (m,10H),5.85-5.96 (m,4H),6.60-6.80 (m,6H),7.26-7.40 (m,5H)

Preparation 121

Boc-MeLeu-D-3,4-MODPhLac-MeLeu-D-Lac-MeLeu-D-3,4-MODPhLac-MeLeu-D-Lac-OBzl (0.59g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBz. Except above matter, Boc-MeLeu-D-3,4-MODPhLac-MeLeu-D-Lac-MeLeu-D-3,4-MODPhLac-MeLeu-D-Lac-OH (0.59g) was obtained according to a similar manner to that of Preparation 25.
 NMR (CDCl₃, δ) :0.75-1.00 (m,24H),1.15-1.82 (m,27H),2.62-3.20 (m,16H),4.56-5.63 (m,8H),5.92 (s,4H),6.60-6.80 (m,6H)

Preparation 122

To a solution of 3-nitro-L-tyrosine (4.52g) in dioxane (40ml) was added 1N sodium hydroxide solution (40ml), and further di-*t*-butyldicarbonate (4.8g) was added and stirred for 1 hour at room temperature. To the reaction was added water (200ml) and extracted with ethyl acetate (100ml × 3). After the ethyl acetate layer was washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and the solvent was evaporated in vacuo. To the residue was added hexane and ether and it was crystallized to give N-(*t*-butoxycarbonyl)-3-nitro-L-tyrosine (6.50g).
 NMR (CDCl₃, δ) :1.42 (s,9H),2.9-3.3 (m,3H),4.6-4.65 (m) and 5.0-5.15(m) (1H),7.09 (d,1H),7.44 (dd,1H),7.93 (d,1H),10.4-10.6 (m,1H)
 IR (KBr):1713,1683cm⁻¹

Preparation 123

To a solution of N-(*t*-butoxycarbonyl)-3-nitro-L-tyrosine (6.49g) in dimethylformamide (50ml) was added potassium carbonate (11.05g). Further methyl iodide (3.7ml) was added and stirred for 15 hours at room temperature. To the reaction solution was added water (500ml) and extracted with ethyl acetate (100ml × 3). After ethyl acetate layer was washed with saturated brine, the residue was dried over anhydrous sodium sulfate. The solvent was evaporated in vacuo. To the residue was added hexane and ether and it was crystallized to give methyl N-(*t*-butoxycarbonyl)-O-methyl-3-nitro-L-tyrosine (6.76g).
 NMR (CDCl₃, δ) :1.42(s,9H),3.00 (dd,1H),3.17 (dd,1H),3.75 (s,3H),3.95 (s,3H),4.5-4.65 (m) and 5.0 - 5.1 (m) (1H),7.02 (d,1H),7.33 (dd,1H), 7.62 (d,1H)
 IR (KBr):1742,1710,1695cm⁻¹

Preparation 124

To a ethanol solution of methyl N-(*t*-butoxycarbonyl)-O-methyl-3-nitro-L-tyrosine (6.74g) was added 1N sodium hydroxide solution (25ml) and was stirred for 2 hours at room temperature. The solvent was evaporated and water (70ml) and 1N hydrochloric acid solution (27.5ml) was added, extracted with ethyl acetate (50ml × 3). After ethyl acetate layer was washed with saturated brine, the residue was dried over anhydrous sodium sulfate. The solvent was evaporated in vacuo. To the residue was added hexane and ether and it was crystallized to give N-(*t*-butoxycarbonyl)-O-methyl-3-nitro-L-tyrosine (6.61g).
 NMR (CDCl₃, δ) :1.42 (s,9H),2.9-3.3 (m,2H),3.95 (s,3H),4.5-4.65 (m) and 5.0-5.1 (m) (1H),7.27 (d,1H),7.39 (dd,1H),7.69 (bs,1H)
 IR (KBr):1727,1652cm⁻¹

Preparation 125

To N-(*t*-butoxycarbonyl)-O-methyl-3-nitro-L-tyrosine (6.60g) was added 4N hydrogen chloride in ethyl acetate solution and was stirred for 1 hour at room temperature. The solvent was evaporated and further it

was azeotroped by toluene to give O-methyl-3-nitro-L-tyrosine hydrochloride (4.95g).

NMR (DMSO - d_6 , δ) :3.1 - 3.2 (m,2H),3.92 (s,3H),4.21 (t,1H),7.35 (d,1H),7.59 (dd,1H),7.83 (d,1H)
IR (KBr):1729cm⁻¹

Preparation 126

To suspension solution of O-methyl-3-nitro-L-tyrosine hydrochloride (4.93g) in 6N aqueous hydrochloric acid was added under ice-cooling, sodium nitrite (1.97g) and was stirred at the same temperature for 1 and 1/2 hour and further at room temperature for 3 hours. The resultant suspension solution was extracted with ethyl acetate (50ml \times 3). After the ethyl acetate layer was washed with saturated brine, dried over anhydrous sodium sulfate. The solvent was evaporated in vacuo to give (S)-2-chloro-3-(4-methoxy-3-nitrophenyl)propionic acid (4.46g).

NMR (CDCl₃, δ) :3.21 (dd,1H),3.39 (dd,1H),3.96 (s,3H),4.49 (dd,1H),7.06 (d,1H),7.45 (dd,1H),7.77 (d,1H)
IR (neat):1726cm⁻¹

Preparation 127

To a ethanol solution of (S)-2-chloro-3-(4-methoxy-3-nitrophenyl)propionic acid (4.46g) was added p-toluenesulfonic acid (0.38g) and heated under reflux for 5 hours. After cooled it down, the solvent was evaporated in vacuo. The resultant suspension solution was extracted by ethyl acetate (50ml \times 3). After the ethyl acetate layer was washed with saturated brine, dried over anhydrous sodium sulfate. The solvent was evaporated in vacuo, the resultant crude product was purified by silica gel column chromatography, and eluted with mixture of hexane or ethyl acetate (4:1, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain ethyl (S)-2-chloro-3-(4-methoxy-3-nitrophenyl)propionate (4.51g).

NMR (CDCl₃, δ) :1.26 (t,3H),3.17 (dd,1H),3.36 (dd,1H),3.96 (s,3H),4.15 (q,2H),4.41 (dd,1H),7.03 (d,1H),7.43 (dd,1H),7.74 (d,1H)
IR (neat):1735cm⁻¹

Preparation 128

To a ethanol solution (50ml) which contain acetic acid (2.3ml) was added cesium carbonate (6.5g) and stirred for a half an hour at room temperature, and the solvent was evaporated to give cesium acetate. Cesium acetate was added to dimethylformamide solution of ethyl (S)-2-chloro-3-(4-methoxy-3-nitrophenyl)propionate (4.51g) and stirred for 4 hours. To the mixture, water (200ml) was added and extracted with ether (100ml \times 1, 50ml \times 2). After ether layer was washed with saturated brine, the residue was dried over anhydrous sodium sulfate and evaporated in vacuo. The resultant crude product was purified by silica gel column chromatography, eluting with a mixed solvent of hexane and ethyl acetate (7:3, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain ethyl (R)-2-acetoxy-3-(4-methoxy-3-nitrophenyl)propionate (1.58g).

NMR (CDCl₃, δ) :1.26 (t,3H),2.11 (s,3H),3.05-3.25 (m,2H),3.95 (s,3H), 4.20 (q,2H),5.19 (dd,1H),7.03 (d,1H),7.42 (dd,1H),7.74 (d,1H)
IR (neat):1742cm⁻¹

Preparation 129

To a ethanol solution (50ml) which contain 37% aqueous formalin solution (4.0ml) of ethyl (R)-2-acetoxy-3-(4-methoxy-3-nitrophenyl)propionate (1.56g) was added 10% palladium on carbon (0.5g) and under atmospheric pressure hydrogenated at room temperature for 4 hours. The catalyst was filtered off and the solvent was evaporated in vacuo. The resultant crude product was purified by silica gel column chromatography, eluting with a mixed solvent of hexane and ethyl acetate (7:3, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain ethyl (R)-2-acetoxy-3-(4-methoxy-3-dimethylaminophenyl)propionate (1.58g).

NMR (CDCl₃, δ) :1.23 (t,3H),2.09 (s,3H),2.77 (s,6H),2.95-3.15 (m,2H), 3.87 (s,3H),4.18 (q,2H),5.15 (dd,1H),6.75-6.9 (m,3H)
IR (neat):1742cm⁻¹

Preparation 130

To a solution of ethyl (R)-2-acetoxy-3-(4-methoxy-3-dimethylaminophenyl)propionate (1.56g) in benzyl alcohol (3.7ml) and benzene (7.4ml) was added p-toluenesulfonic acid (0.82g) and heated under reflux for 6 hours. After cooling, the solvent was evaporated in vacuo, and the gained crude product was purified by silica gel column chromatography. The residue was eluted with mixed solvent of hexane, ethyl acetate, and ethanol (60:35:5, v/v).

The fractions containing the desired product were combined and evaporated in vacuo to obtain benzyl (R)-2-hydroxy-3-(4-methoxy-3-dimethylaminophenyl)propionate (0.93g).

NMR (CDCl_3, δ): 2.68 (d, 1H), 2.74 (s, 6H), 2.92 (dd, 1H), 5.19 (s, 2H), 6.7-6.8 (m, 3H), 7.3-7.4 (m, 5H)
IR (KBr): 1738 cm^{-1}

Preparation 131

H-D-3MA-4MOPhLac-OBzl (0.90g) was used instead of H-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-3MA-4MOPhLac-MeLeu-D-Lac-OBzl (1.40g) was obtained according to a similar manner to that of Preparation 24.

NMR (CDCl_3, δ): 0.89 (d, 6H), 1.41 (s) and 1.47 (s) (9H), 1.4-1.6 (m, 3H), 2.65 (s) and 2.68 (s) (3H), 2.75 (s, 6H), 3.1-3.2 (m, 2H), 3.85 (s, 3H), 4.6-4.75 (m) and 4.95-5.3 (m) (4H), 6.7-6.8 (m, 3H), 7.2-7.4 (m, 5H)
IR (KBr): 1741, 1695 cm^{-1}

Preparation 132

Boc-MeLeu-D-3MA-4MOPhLac-OBzl (1.38g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-3MA-4MOPhLac-OH (1.16g) was obtained according to a similar manner to that of Preparation 25.
IR (KBr): 1740, 1694 cm^{-1}

Preparation 133

Boc-MeLeu-D-3MA-4MOPhLac-OH (1.16g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH. Except above matter, Boc-MeLeu-D-3MA-4MOPhLac-MeLeu-D-Lac-OBzl (1.80g) was obtained according to a similar manner to that of Preparation 26.

NMR (CDCl_3, δ): 0.8-1.1 (m, 12H), 1.35-1.7 (m, 18H), 2.65-3.1 (m, 12H), 3.0-3.1 (m, 2H), 3.85 (s, 3H), 4.60-3.8 (m) and 4.9-5.5 (m) (6H), 6.7-6.85 (m, 3H), 7.3-7.4 (m, 5H)
IR (KBr): 1740, 1694, 1664 cm^{-1}

Preparation 134

Boc-MeLeu-D-3MA-4MOPhLac-MeLeu-D-Lac-OBzl (0.90g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-3MA-4MOPhLac-MeLeu-D-Lac-OH (0.85g) was obtained according to a similar manner to that of Preparation 25.
IR (KBr): 1740, 1696, 1662 cm^{-1}

Preparation 135

Boc-MeLeu-D-3MA-4MOPhLac-MeLeu-D-Lac-OBzl (0.90g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl. Except above matter, 2HCl·H-MeLeu-D-3MA-4MOPhLac-MeLeu-D-Lac-OBzl (0.97g) was obtained according to a similar manner to that of Preparation 28.
IR (KBr): 1744, 1648 cm^{-1}

Preparation 136

Boc-MeLeu-D-3MA-4MOPhLac-MeLeu-D-Lac-OH (0.84g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH, and 2HCl·H-MeLeu-D-3MA-4MOPhLac-MeLeu-D-Lac-OBzl (0.96g) was used instead of HCl·H-MeLeu-D-Lac-OBzl. Except above matter, Boc-MeLeu-D-3MA-4MOPhLac-MeLeu-D-Lac-MeLeu-D-3MA-4MOPhLac-MeLeu-D-Lac-OBzl (1.15g) was obtained according to a similar manner to that of Preparation 26.

NMR (CDCl₃, δ) :0.75-1.05 (m, 24H), 1.3-1.8 (m, 27H), 2.6-3.2 (m, 16H), 2.77 (s, 12H), 3.85 (s, 6H), 4.65-4.75 (m) and 4.9 - 5.5 (m) (10H), 6.7-6.9 (m, 6H), 7.3-7.4 (m, 5H)

IR (KBr): 1740, 1694, 1663 cm⁻¹

FAB-MS: 1303 [M + H]⁺

Preparation 137

Boc-MeLeu-D-3MA-4MOPhLac-MeLeu-D-Lac-MeLeu-D-3MA-4MOPhLac-MeLeu-D-Lac-OBzl (1.14g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-3MA-4MOPhLac-MeLeu-D-Lac-MeLeu-D-3MA-4MOPhLac-MeLeu-D-Lac-OH (1.09g) was obtained according to a similar manner to that of Preparation 25.

IR (KBr): 1740, 1694, 1663 cm⁻¹

Preparation 138

Boc-MeLeu-D-3MA-4MOPhLac-MeLeu-D-Lac-MeLeu-D-3MA-4MOPhLac-MeLeu-D-Lac-OH (1.08g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl. Except above matter, 3HCl·H-MeLeu-D-3MA-4MOPhLac-MeLeu-D-Lac-MeLeu-D-3MA-4MOPhLac-MeLeu-D-Lac-OH (1.19g) was obtained according to a similar manner to that of Preparation 28.

IR (KBr): 1741, 1646 cm⁻¹

Preparation 139

To a dichloromethane solution of ethyl D-2-hydroxy-3-(4-aminophenyl)propionate (4.2g) were added under ice-cooling, triethylamine (7.36ml), acetyl chloride (2.5g) at room temperature for 2 and 1/2 hours. The reaction solution was poured into aqueous saturated sodium bicarbonate solution, and extracted with dichloromethane. After drying by magnesium sulfate, the solvent was evaporated in vacuo and then purified by silica gel column chromatography, eluting with a mixed solvent of hexane and ethyl acetate (1:1, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain ethyl (R)-3-(4-acetamidophenyl)-2-acetoxypropionate (3.42g).

NMR (CDCl₃, δ) :1.24 (t, 3H), 2.08 (s, 3H), 2.16 (s, 3H), 3.06-3.20 (m, 2H), 4.17 (q, 2H), 5.12-5.20 (m, 1H), 7.17 (d, 2H)-7.43 (d, 2H)

Preparation 140

To an anhydrous acetic acid solution of ethyl (R)-3-(4-acetamidophenyl)-2-acetoxypropionate (3.12g) was added dropwise under ice-cooling, fuming nitric acid (3ml)-acetic anhydride (7.5ml), and stirred for a half an hour successively. The reaction solution was poured into aqueous saturated sodium bicarbonate solution, after the neutralization, extracted with ethyl acetate and washed with saturated brine. After drying by magnesium sulfate, the solvent was evaporated in vacuo to give ethyl (R)-3-(4-acetamide-3-nitrophenyl)-2-acetoxypropionate (3.98g)

NMR (CDCl₃, δ) :1.25 (t, 3H), 2.11 (s, 3H), 2.29 (s, 3H), 3.10-3.25 (m, 2H), 4.50 (q, 2H), 5.17-5.24 (m, 1H), 7.52 (dd, 1H), 8.10 (d, 1H), 8.72 (d, 1H)

Preparation 141

To a solution of ethyl (R)-3-(4-acetamide-3-nitrophenyl)-2-acetoxypropionate (3.9g) in ethanol (120ml) was added concentrated hydrochloric acid and heated under reflux for 75 minutes. After ethanol was evaporated in vacuo, aqueous saturated sodium bicarbonate solution was added, extracted with ethyl acetate, and washed with saturated sodium chloride. After drying by magnesium sulfate, the solvent was evaporated in vacuo to give ethyl (R)-3-(4-amino-3-nitrophenyl)-2-hydroxypropionate (2.59g).

NMR (CDCl₃, δ) :1.32 (t, 3H), 2.89 (dd, 1H), 3.05 (dd, 1H), 4.23 (q, 2H), 4.35-4.50 (m, 1H), 6.74 (d, 1H), 7.30 (dd, 1H)-7.30 (d, 1H)

Preparation 142

To a solution of ethyl (R)-3-(4-amino-3-nitrophenyl)-2-hydroxypropionate (0.8g) in methanol (8ml) and water (5ml) were added iron powder (1g), acetic acid (0.8ml) and heated under reflux for a half an hour.

After the reaction solution was filtered through celite, methanol was evaporated in vacuo. After the residue was neutralized with aqueous sodium bicarbonate solution, the residue was extracted with ethyl acetate. After drying by magnesium sulfate, the solvent was evaporated in vacuo, and dissolved in acetic acid. To the mixture paraformaldehyde (0.56g), and sodium cyanoborohydride (0.59g) were added and stirred for 19 hours at room temperature. The reaction solution was added to aqueous solution saturated with sodium bicarbonate, and after the residue was neutralized with aqueous sodium bicarbonate solution, extracted with ethyl acetate, and dried over sodium sulfate. The solvent was evaporated in vacuo and then purified by silica gel column chromatography, eluting with a mixed solvent of hexane and ethyl acetate (3:2, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain ethyl (R)-3-[3,4-bis(dimethylamino)phenyl]-2-hydroxypropionate (0.3g).

NMR (CDCl₃, δ) :1.29 (t,3H), 2.65 (s,6H), 2.77 (s,6H), 2.75-3.16 (m,2H), 4.23 (q,2H), 4.35-4.50 (m,1H), 6.70-6.83 (m,2H), 7.21-7.26 (m,1H) EI-MS:281 [M]⁺

Preparation 143

To a solution of ethyl (R)-3-[3,4-bis(dimethylamino) phenyl]-2-hydroxypropionate (0.54g) in benzene were added benzyl alcohol (2ml) and p-toluenesulfonic acid (0.8g) and heated under reflux for 5 hours. The reaction solution was added to aqueous dilute hydrochloric acid, after washing with ethyl acetate, the water layer was neutralized with aqueous saturated sodium bicarbonate, and extracted with ethyl acetate. After washing with saturated sodium chloride, dried over sodium sulfate. After the solvent was evaporated in vacuo, purified by silica gel column chromatography, eluting with a mixed solvent of hexane and ethyl acetate (3:1, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain benzyl (R)-3-[3,4-bis(dimethylamino)phenyl]-2-hydroxypropionate (0.3g).

NMR (CDCl₃, δ) :2.74 (s,6H), 2.75 (s,6H), 2.91 (dd,1H), 3.05 (dd,1H), 4.40-4.55 (m,1H), 5.15 (d,1H), 5.22 (d,1H), 6.60-6.80 (m,3H), 7.25-7.40 (m,5H)

IR (KBr):1734cm⁻¹

Preparation 144

H-D-3,4-DMAPhLac-OBzl (0.32g) was used instead of H-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-3,4-DMAPhLac-OBzl (0.59g) was obtained according to a similar manner to that of Preparation 24.

NMR (CDCl₃, δ) :0.89 (d,6H), 1.32-1.60 (m,12H), 2.60-2.70 (m,3H), 2.75 (s,12H), 3.00-3.20 (m,2H), 4.62-5.30 (m,4H), 6.65-6.78 (m,3H), 7.20-7.40 (m,5H)

Preparation 145

Boc-MeLeu-D-3,4-DMAPhLac-OBzl (0.59g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-3,4-DMAPhLac-OH (0.47g) was obtained according to a similar manner to that of Preparation 25.

NMR (CDCl₃, δ) :0.89 (d,6H), 1.20-1.80 (m,12H), 2.60-2.85 (m,15H), 3.00-3.28 (m,2H), 4.30-4.80 (m) and 5.18-5.37 (m) (2H), 6.78-6.90 (m,3H)

Preparation 146

Boc-MeLeu-D-3,4-DMAPhLac-OH (0.47g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH. Except above matter, Boc-MeLeu-D-3,4-DMAPhLac-MeLeu-D-Lac-OBzl (0.67g) was obtained according to a similar manner to that of Preparation 26.

NMR (CDCl₃, δ) :0.77-1.00 (m,12H), 1.38-1.70 (m,18H), 2.71-3.18 (m,20H), 4.60-5.57 (m,6H), 6.66-6.80 (m,3H), 7.22-7.38 (m,5H)

Preparation 147

Boc-MeLeu-D-3,4-DMAPhLac-MeLeu-D-Lac-OBzl (0.34g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-3,4-DMAPhLac-MeLeu-D-Lac-OH (0.30g) was obtained according to a similar manner to that of Preparation 25.

NMR (CDCl₃, δ) :0.78-1.08 (m,12H), 1.20-1.75 (m,18H), 2.62-3.23 (m,20H), 4.60-5.82 (m,4H), 6.72-6.84 (m,3H)

Preparation 148

Boc-MeLeu-D-3,4-DMAPhLac-MeLeu-D-Lac-OBzl (0.33g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl. Except above matter, 3HCl•H-MeLeu-D-3,4-DMAPhLac-MeLeu-D-Lac-OBzl (0.30g) was obtained according to a similar manner to that of Preparation 28.

NMR (CDCl₃, δ) :0.76-1.12 (m, 12H), 1.25-2.20 (m, 9H), 2.60-4.20 (m, 21H), 5.05-5.60 (m, 5H), 7.20-7.62 (m, 7H), 8.30-8.50 (m, 1H), 9.42-9.70 (m, 1H), 10.92-11.20 (m, 1H)

Preparation 149

Boc-MeLeu-D-3,4-DMAPhLac-MeLeu-D-Lac-OH (0.30g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH, 3HCl•H-MeLeu-D-3,4-DMAPhLac-MeLeu-D-Lac-OBzl (0.30g) was used instead of HCl•H-MeLeu-D-Lac-OBzl. Except above matter, Boc-MeLeu-D-3,4-DMAPhLac-MeLeu-D-Lac-MeLeu-D-3,4-DMAPhLac-MeLeu-D-Lac-OBzl (0.35g) was obtained according to a similar manner to that of Preparation 26.

NMR (CDCl₃, δ) :0.78-1.00 (m, 24H), 1.20-1.80 (m, 27H), 2.63-3.18 (m, 40H), 4.90-5.60 (m, 10H), 6.65-6.80 (m, 6H), 7.22-7.38 (m, 5H)

FAB-MS:1330 [M + H]⁺

Preparation 150

Boc-MeLeu-D-3,4-DMAPhLac-MeLeu-D-Lac-MeLeu-D-3,4-DMAPhLac-MeLeu-D-Lac-OBzl (0.34g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-3,4-DMAPhLac-MeLeu-D-Lac-MeLeu-D-3,4-DMAPhLac-MeLeu-D-Lac-OH (0.35g) was obtained according to a similar manner to that of Preparation 25.

NMR (CDCl₃, δ) :0.78-1.07 (m, 24H), 1.10-1.80 (m, 27H), 2.30-3.20 (m, 40H), 4.60-5.74 (m, 8H), 6.70-6.82 (m, 6H)

Preparation 151

(S)-2-fluorophenyl alanine (3.00g) was dissolved in 6N-aqueous hydrochloric acid (80ml) and at 0 °C sodium nitrite (3.01g) was added gradually. After the mixture was stirred for 4 hours successively, the temperature was increased back to room temperature. To the mixture was added sodium nitrite (1.13g), stirred further for 2 hours, added water (200ml), and extracted with ether (150ml × 1, 100ml × 2). The ether layer was washed with a solution (saturated brine: water = 1:1, v/v) (100ml × 2), dried over calcium chloride, and the solvent was evaporated in vacuo. To the residue, benzene (20ml), benzylalcohol (1.32ml) and p-toluenesulfonic acid•mono hydrate (0.33g) were added and heated under reflux for an hour using Dean-stark apparatus. After cooling down to room temperature, the crude product, which was gained by evaporating the solvent, was purified by silica gel chromatography, eluting with a mixed solvent of ethyl acetate and hexane (1:19V/V). The fractions containing the desired product were combined and evaporated in vacuo to obtain benzyl (S)-2-chloro-3-(2-fluorophenyl) propionate (2.24g).

NMR (CDCl₃, δ) :3.25 (dd, 1H), 3.40 (dd, 1H), 4.57 (t, 1H), 5.16 (s, 2H), 6.98-7.40 (m, 9H)

EI-MS:292 [M]⁺

Preparation 152

Benzyl (S)-2-chloro-3-(2-fluorophenyl)propionate (0.90g) was used instead of benzyl (S)-2-chloro-3-(4-methoxyphenyl)propionate. Except above matter, Boc-MeLeu-D-o-FPhLac-OBzl (1.30g) was obtained according to a similar manner to that of Preparation 2.

NMR (CDCl₃, δ) :0.89 (d, 6H), 1.38-1.63 (m, 12H), 2.58-2.70 (m, 3H), 3.10-3.38 (m, 2H), 4.6-4.78 (m) and 5.1-5.38 (m) (4H), 6.97-7.42 (m, 9H)

FAB-MS:402 [M-Boc + H]⁺

Preparation 153

Boc-MeLeu-D-o-FPhLac-OBzl (1.26g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-o-FPhLac-OH (1.07g) was obtained according to a similar manner to that of Preparation 25.

NMR (CDCl₃, δ) :0.82-1.02 (m, 6H), 1.19-1.82 (m, 12H), 2.63-2.88 (m, 3H), 3.08-3.9 (m, 2H), 4.26-4.42 (m) and 4.6-4.8 (m) and 5.23-5.44 (m) (2H), 6.99-7.4 (m, 4H)

Preparation 154

Boc-MeLeu-D-o-FPhLac-OH (1.03g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH. Except above matter, Boc-MeLeu-D-o-FPhLac-MeLeu-D-Lac-OBzl (1.45g) was obtained according to a similar manner to that of Preparation 26.

NMR (CDCl₃, δ) :0.80-1.05 (m,12H),1.18-1.83 (m,18H),2.7-3.2 (m,8H),4.6-4.8 (m) and 4.88-5.6 (m) (6H),6.99-7.43 (m,9H)

FAB-MS:601 [M-Boc + H]⁺

Preparation 155

Boc-MeLeu-D-o-FPhLac-MeLeu-D-Lac-OBzl (0.70g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-o-FPhLac-MeLeu-D-Lac-OH (0.57g) was obtained according to a similar manner to that of Preparation 25.

NMR (CDCl₃, δ) :0.79-1.03 (m,12H),1.08-1.85 (m,18H),2.59-3.38 (m,8H),4.6-4.98 (m) and 5.05-5.6 (m) and 5.83-6.0 (m) (4H), 6.99-7.38 (m,4H)

Preparation 156

Boc-MeLeu-D-o-FPhLac-MeLeu-D-Lac-OBzl (0.61g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl. Except above matter, HCl•H-MeLeu-D-o-FPhLac-MeLeu-D-Lac-OBzl (0.53g) was obtained according to a similar manner to that of Preparation 28.

NMR (CDCl₃, δ) :0.62-1.03 (m,12H),1.2-2.05 (m,9H),2.58-2.75 (m,3H),2.98-3.36 (m,5H),3.62-3.82 (m,1H),5.02-5.38 (m) and 5.46-5.63 (m) (5H),6.99-7.43 (m,9H)

Preparation 157

Boc-MeLeu-D-o-FPhLac-MeLeu-D-Lac-OH (0.55g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH, and HCl•H-MeLeu-D-o-FPhLac-MeLeu-D-Lac-OBzl (0.51g) was used instead of HCl•H-MeLeu-D-Lac-OBzl. Except above matter, Boc-MeLeu-D-o-FPhLac-MeLeu-D-Lac-MeLeu-D-o-FPhLac-MeLeu-D-Lac-OBzl (0.97g) was obtained according to a similar manner to that of Preparation 26.

NMR (CDCl₃, δ) :0.78-1.04 (m,24H),1.10-1.82 (m,27H),2.7-3.23 (m,16H),4.6-4.8 (m) and 5.02-5.61 (m) (10H)-6.98-7.42 (m,13H)

FAB-MS:1093 [M-Boc + H]⁺

Preparation 158

Boc-MeLeu-D-o-FPhLac-MeLeu-D-Lac-MeLeu-D-o-FPhLac-MeLeu-D-Lac-OBzl (0.89g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-o-FPhLac-MeLeu-D-Lac-MeLeu-D-o-FPhLac-MeLeu-D-Lac-OH (0.84g) was obtained according to a similar manner to that of Preparation 25.

NMR (CDCl₃, δ) :0.78-1.05 (m,24H),1.12-1.82 (m,27H),2.62-3.29 (m,16H),4.5-5.87 (m,8H),6.98-7.38 (m,8H)

Preparation 159

(S)-3-fluorophenylalanine (5.20g) was used instead of (S)-2-fluorophenylalanine. Except above matter, benzyl (S)-2-chloro-3-(3-fluorophenyl)propionate (7.04g) was obtained according to a similar manner to that of Preparation 151.

NMR (CDCl₃, δ) :3.17 (dd,1H),3.36 (dd,1H),4.47 (t,1H),5.17 (s,2H), 6.82-7.04 (m,3H),7.18-7.5 (m,6H)

EI-MS:292 [M]⁺

Preparation 160

Benzyl (S)-2-chloro-3-(3-fluorophenyl)propionate (1.76g) was used instead of benzyl (S)-2-chloro-3-(4-methoxyphenyl)propionate. Except above matter, Boc-MeLeu-D-m-FPhLac-OBzl (1.13g) was obtained according to a similar manner to that of Preparation 2.

NMR (CDCl₃, δ) :0.9 (d,6H),1.39-1.78 (m,12H),2.6-2.77 (m,3H), 3.03-3.22 (m,2H),4.63-4.79 (m) and 4.92-5.36 (m) (4H),6.8-7.0 (m,3H), 7.18-7.42 (m,6H)

FAB-MS:402 [M-Boc + H]⁺

Preparation 161

Boc-MeLeu-D-m-FPhLac-OBzl (1.11g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-m-FPhLac-OH (1.00g) was obtained according to a similar manner to that of Preparation 25.

NMR (CDCl₃, δ) :0.82-1.00 (m,6H),1.2-1.8 (m,12H),2.76-2.85 (m,3H),3.02-3.25 (m,2H),4.38-4.5 (m) and 4.62-4.79 (m) and 5.19-5.41 (m) (2H),6.86-7.04 (m,3H),7.19-7.38 (m,1H)

Preparation 162

Boc-MeLeu-D-m-FPhLac-OH (0.99g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH. Except above matter, Boc-MeLeu-D-m-FPhLac-MeLeu-D-Lac-OBzl (1.32g) was obtained according to a similar manner to that of Preparation 26.

NMR (CDCl₃, δ) :0.80-1.01 (m,12H),1.39-1.79 (m,18H),2.73-3.18 (m,8H),5.03-5.57 (m,6H),6.88-7.07 (m,3H)-7.21-7.42 (m,6H)

FAB-MS:601 [M-Boc + H]⁺

Preparation 163

Boc-MeLeu-D-m-FPhLac-MeLeu-D-Lac-OBzl (0.65g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-m-FPhLac-MeLeu-D-Lac-OH (0.69g) was obtained according to a similar manner to that of Preparation 25.

NMR (CDCl₃, δ) :0.8-1.02 (m,12H),1.1-1.8 (m,18H),2.63-3.3 (m,8H), 4.62-5.59 (m) and 5.73-5.85 (m) (4H)-6.83-7.1 (m,3H),7.19-7.38 (m,1H)

Preparation 164

Boc-MeLeu-D-m-FPhLac-MeLeu-D-Lac-OBzl (0.65g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl. Except above matter, HCl•H-MeLeu-D-m-FPhLac-MeLeu-D-Lac-OBzl (0.59g) was obtained according to a similar manner to that of Preparation 28.

NMR (CDCl₃, δ) :0.69-1.03 (m,12H),1.18-2.03 (m,9H),2.58-2.7 (m,3H),2.82-3.0 (m,3H),3.03-3.21 (m,2H),3.62-3.82 (m,1H),5.01-5.38 (m) and 5.41-5.58 (m) (5H),6.94-7.07 (m,3H),7.17-7.43 (m,6H)

Preparation 165

Boc-MeLeu-D-m-FPhLac-MeLeu-D-Lac-OH (0.69g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH, HCl•H-MeLeu-D-m-FPhLac-MeLeu-D-Lac-OBzl (0.59g) was used instead of HCl•H-MeLeu-D-Lac-OBzl. Except above matter, Boc-MeLeu-D-m-FPhLac-MeLeu-D-Lac-MeLeu-D-m-FPhLac-MeLeu-D-Lac-OBzl (1.06g) was obtained according to a similar manner to that of Preparation 26.

NMR (CDCl₃, δ) :0.77-1.04 (m,24H),1.04-1.95 (m,27H),2.6-3.3 (m,16H),4.62-4.79 (m) and 4.88-5.58 (m) (10H)-6.82-7.14 (m,6H), 7.19-7.42(m,7H)

FAB-MS:1094 [M-Boc + H]⁺

Preparation 166

Boc-MeLeu-D-m-FPhLac-MeLeu-D-Lac-MeLeu-D-m-FPhLac-MeLeu-D-Lac-OBzl (0.97g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-m-FPhLac-MeLeu-D-Lac-MeLeu-D-m-FPhLac-MeLeu-D-Lac-OH (0.81g) was obtained according to a similar manner to that of Preparation 25.

NMR (CDCl₃, δ) :0.77-1.05 (m,24H),1.05-1.83 (m,27H),2.58-3.22 (m,16H),4.6-4.79 (m) and 4.88-5.78 (m) (8H)-6.85-7.08 (m,6H), 7.18-7.39 (m,2H)

Preparation 167

(S)-4-fluorophenylalanine (5.00g) was used instead of (S)-2-fluorophenylalanine. Except above matter, benzyl (S)-2-(S)-2-chloro-3-(4-fluorophenyl)propionate (1.8g) was obtained according to a similar manner to that of Preparation 151.

NMR (CDCl₃, δ) :3.16 (dd,1H),3.33 (dd,1H),4.44 (t,1H),5.15 (s,2H), 6.88-7.42 (m,9H)

EI-MS:292 [M]⁺

Preparation 168

- 5 Benzyl (S)-2-chloro-3-(4-fluorophenyl)propionate (2.21g) was used instead of benzyl (S)-2-chloro-3-(4-methoxyphenyl)propionate. Except above matter, Boc-MeLeu-D-p-FPhLac-OBzl (1.55g) was obtained according to a similar manner to that of Preparation 2.
NMR (CDCl₃, δ) :0.9 (d,6H),1.3-1.62 (m,12H),2.58-2.67 (m,3H), 3.0-3.12 (m,2H),4.6-4.79 (m) and 4.9-5.27 (m) (4H),6.9-7.42 (m,9H)
- 10 FAB-MS:402 [M-Boc + H]⁺

Preparation 169

- 15 Boc-MeLeu-D-p-FPhLac-OBzl (1.45g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-p-FPhLac-OH (1.25g) was obtained according to a similar manner to that of Preparation 25.
NMR (CDCl₃, δ) :0.83-1.00 (m,6H),1.41-1.78 (m,12H),2.7-2.84 (m,3H),3.02-3.23 (m,2H),4.41-5.39 (m,3H),6.9-7.06 (m,2H),7.1-7.26 (m,2H)

20 Preparation 170

- Boc-MeLeu-D-p-FPhLac-OH (1.23g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH. Except above matter, Boc-MeLeu-D-p-FPhLac-MeLeu-D-Lac-OBzl (2.06g) was obtained according to a similar manner to that of Preparation 26.
- 25 NMR (CDCl₃, δ) :0.7-1.04 (m,12H),1.1-1.97 (m,18H),2.63-2.96 (m,6H),3.0-3.18 (m,2H),4.6-5.5 (m,6H),6.88-7.1 (m,2H),7.15-7.5 (m,7H)
FAB-MS:601 [M-Boc + H]⁺

Preparation 171

- 30 Boc-MeLeu-D-p-FPhLac-MeLeu-D-Lac-OBzl (0.9g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-p-FPhLac-MeLeu-D-Lac-OH (0.78g) was obtained according to a similar manner to that of Preparation 25.
NMR (CDCl₃, δ) :0.8-1.02 (m,12H),1.05-1.8 (m,18H),2.62-3.3 (m,8H),4.6-5.85 (m,4H),6.88-7.05 (m,2H),7.12-7.28 (m,2H)
- 35

Preparation 172

- 40 Boc-MeLeu-D-p-FPhLac-MeLeu-D-Lac-OBzl (0.89g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl. Except above matter, HCl•H-MeLeu-D-p-FPhLac-MeLeu-D-Lac-OBzl (0.85g) was obtained according to a similar manner to that of Preparation 28.
NMR (CDCl₃, δ) :0.68-1.05 (m,12H),1.18-2.05 (m,9H),2.53-2.68 (m,3H),2.82-3.0 (m,3H),3.0-3.18 (m,2H),3.63-3.81 (m,1H),5.02-5.38 (m,4H),5.4-5.59 (m,1H),6.96-7.07 (m,2H),7.15-7.42 (m,7H)

45 Preparation 173

- Boc-MeLeu-D-p-FPhLac-MeLeu-D-Lac-OH (0.77g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH and HCl•H-MeLeu-D-p-FPhLac-MeLeu-D-Lac-OBzl (0.84g) was used instead of HCl•H-MeLeu-D-Lac-OBzl. Except above matter, Boc-MeLeu-D-p-FPhLac-MeLeu-D-Lac-MeLeu-D-p-FPhLac-MeLeu-D-Lac-OBzl (1.32g) was obtained according to a similar manner to that of Preparation 26.
- 50 NMR (CDCl₃, δ) :0.78-1.07 (m,24H),1.13-1.9 (m,27H),2.62-3.28 (m,16H),4.6-4.8 (m) and 4.9-5.57 (m) (10H)-6.86-7.07 (m,4H), 7.07-7.42 (m,9H)
FAB-MS:1094 [M-Boc + H]⁺

55 Preparation 174

Boc-MeLeu-D-p-FPhLac-MeLeu-D-Lac-MeLeu-D-p-FPhLac-MeLeu-D-Lac-OBzl (1.31g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-p-FPhLac-MeLeu-D-Lac-MeLeu-

D-p-FPhLac-MeLeu-D-Lac-OH (0.99g) was obtained according to a similar manner to that of Preparation 25. NMR (CDCl₃, δ) :0.79-1.05 (m, 24H), 1.18-1.93 (m, 27H), 2.62-3.24 (m, 16H), 4.58-5.8 (m, 8H), 6.88-7.04 (m, 4H), 7.1-7.38 (m, 4H)

5 Preparation 175

Boc-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-OH (0.96g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH, and HCl·H-MeLeu-D-PhLac-MeLeu-D-Lac-OBzl (1.42g) was used instead of, HCl·H-MeLeu-D-Lac-OBzl. Except above matter, Boc-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-MeLeu-D-PhLac-MeLeu-D-Lac-OH (1.28g) was obtained according to a similar manner to that of Preparation 26. NMR (CDCl₃, δ) :0.77-1.02 (m, 24H), 1.02-1.96 (m, 27H), 2.6-3.25 (m, 16H), 3.78 (s, 3H), 4.6-4.8 (m) and 4.95-5.57 (m) (10H), 6.78-6.90 (m, 2H), 7.04-7.4 (m, 12H) FAB-MS:1087 [M-Boc + H]⁺

15 Preparation 176

Boc-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-MeLeu-D-PhLac-MeLeu-D-Lac-OBzl (1.13g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-MeLeu-D-PhLac-MeLeu-D-Lac-OH (0.98g) was obtained according to a similar manner to that of Preparation 25. NMR (CDCl₃, δ) :0.72-1.04 (m, 24H), 1.04-1.9 (m, 27H), 2.6-3.25 (m, 16H), 3.78 (s, 3H), 4.58-4.8 (m) and 4.82-5.56 (m) and 5.65-5.82 (m) (8H), 6.78-6.9 (m, 2H), 7.03-7.38 (m, 7H)

Preparation 177

Benzyl chloroacetate (1.85g) was used instead of benzyl (S)-2-chloro-3-(4-methoxyphenyl)propionate. Except above matter, Boc-MeLeu-Glycol-OBzl (4.0g) was obtained according to a similar manner to that of Preparation 2. NMR (CDCl₃, δ) :0.93 (d, 6H), 1.45 (s, 9H), 1.4-1.8 (m, 3H), 2.78 (s) and 2.80 (s) (3H), 4.6-5.0 (m, 3H), 5.29 (s, 2H), 7.35 (s, 5H) IR (KBr):1740, 1695cm⁻¹

Preparation 178

Boc-MeLeu-Glycol-OBzl (1.50g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl. Except above matter, HCl·H-MeLeu-Glycol-OBzl (1.32g) was obtained according to a similar manner to that of Preparation 28. IR (KBr):1753cm⁻¹

Preparation 179

Boc-MeLeu-D-p-MeOPhLac-OH (0.69g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH, and HCl·H-MeLeu-Glycol-OBzl (0.59g) was used instead of HCl·H-MeLeu-D-Lac-OBzl. Except above matter, Boc-MeLeu-D-p-MeOPhLac-MeLeu-Glycol-OBzl (0.79g) was obtained according to a similar manner to that of Preparation 26. NMR (CDCl₃, δ) :0.8-1.0 (m, 12H), 1.2-1.8 (m, 6H), 1.42 (s) and 1.47 (s) (9H), 2.7-3.0 (m, 6H), 3.03 (d, 2H), 3.78 (s, 3H), 4.66 (s, 2H), 4.6-5.5 (m, 3H), 5.28 (s, 2H), 6.82 (d, 2H), 7.14 (d, 2H), 7.3-7.4 (m, 5H) IR (KBr):1740, 1694, 1664cm⁻¹ APCI-MS:599 [M + H]⁺

50 Preparation 180

Boc-MeLeu-D-p-MeOPhLac-MeLeu-Glycol-OBzl (0.39g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-p-MeOPhLac-MeLeu-Glycol-OH (0.32g) was obtained according to a similar manner to that of Preparation 25. IR (KBr):1744, 1691, 1663cm⁻¹

Preparation 181

Boc-MeLeu-D-p-MeOPhLac-MeLeu-Glycol-OBzl (0.39g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl. Except above matter, HCl•H-MeLeu-D-p-MeOPhLac-MeLeu-Glycol-OBzl (0.38g) was obtained according to a similar manner to that of Preparation 28.

IR (KBr):1745,1653cm⁻¹

Preparation 182

Boc-MeLeu-D-p-MeOPhLac-MeLeu-Glycol-OH (0.32g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OH, and HCl•H-MeLeu-D-p-MeOPhLac-MeLeu-Glycol-OBzl (0.37g) was used instead of HCl•H-MeLeu-D-Lac-OBzl. Except above matter, Boc-MeLeu-D-p-MeOPhLac-MeLeu-Glycol-MeLeu-D-p-MeOPhLac-MeLeu-Glycol-OBzl (0.603g) was obtained according to a similar manner to that of Preparation 26.

NMR (CDCl₃,δ) :0.8-1.05 (m,24H),1.41 (s) and 1.47 (s) (9H), 1.2-1.9 (m,12H),2.65-3.1 (m,16H),3.78 (s,6H)-4.60-4.85 (m) and 5.15-5.5 (m) (10H),5.16 (s,2H),6.75-6.90 (m,2H),7.05-7.2 (m,2H), 7.3-7.4 (m,5H)

IR (KBr):1744,1689,1667cm⁻¹

FAB-MS:1189 [M + H]⁺

Preparation 183

Boc-MeLeu-D-p-MeOPhLac-MeLeu-Glycol-MeLeu-D-p-MeOPhLac-MeLeu-Glycol-OBzl (0.58g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-OBzl. Except above matter, Boc-MeLeu-D-p-MeOPhLac-MeLeu-Glycol-MeLeu-D-p-MeOPhLac-MeLeu-Glycol-OH (0.55g) was obtained according to a similar manner to that of Preparation 25.

IR (KBr):1742,1664cm⁻¹

Preparation 184

Boc-MeLeu-D-p-MeOPhLac-MeLeu-Glycol-MeLeu-D-p-MeOPhLac-MeLeu-Glycol-OH (0.55g) was used instead of Boc-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-OBzl. Except above matter, HCl•H-MeLeu-D-p-MeOPhLac-MeLeu-Glycol-MeLeu-D-p-MeOPhLac-MeLeu-Glycol-OH (0.53g) was obtained according to a similar manner to that of Preparation 28.

IR (KBr):1741,1646cm⁻¹

Example 1

To a solution of Boc-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-OC₆F₅ (0.4g) in methylene chloride (4ml) was added under ice-cooling, trifluoroacetic acid (2ml) and stirred for 2 hours successively. The solvent was evaporated in vacuo, and the residue was dissolved in dioxane (30ml). After adding the mixture dropwise for 5 hours into pyridine (629ml) which was heated at 90 °C, it was stirred for 2 and 1/2 hours successively. The solvent was evaporated in vacuo, azeotroped by toluene (30ml). To the residue was added ethyl acetate (200ml), washed with 10 % aqueous citric acid solution, water, aqueous saturated sodium bicarbonate solution, water in order, dried over anhydrous sodium sulfate, and concentrated in vacuo. The resultant crude product was purified by silica gel chromatography, and eluted with mixture of ethyl acetate and hexane (1.5:1, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain

MeLeu - D - p - MeOPhLac - MeLeu - D - Lac - MeLeu - D - p - MeOPhLac - MeLeu - D - Lac

(0.16g).

NMR (CDCl₃,δ) :0.79-1.00 (m,24H), 1.10-1.80 (m,18H), 2.73-3.09 (m,16H), 3.78 (s,6H), 4.40-4.54 (m), and 5.00-5.67 (m) (8H), 6.82 (d,4H) 7.15 (d,4H).


IR (KBr) : 1741, 1662cm⁻¹

FAB-MS : 1009 (M + H)⁺

Example 2

Boc-MeLeu-D-Man-MeLeu-D-Lac-MeLeu-D-Man-MeLeu-D-Lac-OC₆F₅ was used instead of Boc-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-OC₆F₅. Except above matter,

5



10

(0.11g) was obtained according to a similar manner to that of Example 1.

NMR (CDCl₃, δ) : 0.70-1.00 (m, 24H), 1.10-1.98 (m, 18H), 2.75-3.10 (m, 12H), 4.60-5.70 (m, 6H), 6.44 (s, 2H), 7.30-7.60 (m, 10H).


IR (KBr): 1750, 1677cm⁻¹,

15 FAB-MS : 921 (M + H)⁺

Example 3

To a solution of 3HCl•H-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-MeLeu-D-p-Me₂NPhLac-MeLeu-D-Lac-
20 OH (0.825g) in dichloromethane was (700ml) was added under ice-cooling, triethylamine (0.45ml) and bis(2-oxo-3-oxazolidinyl) phosphinic chloride (0.27g), and stirred for 14 hours successively, and further stirred for 4 hours at room temperature. The solvent was evaporated in vacuo, was added water (50ml), and extracted with ethyl acetate (40ml × 3). The ethyl acetate layer was washed with saturated brine, dried over anhydrous sodium sulfate. The solvent was evaporated in vacuo, the resultant crude product was purified
25 by silica gel chromatography, and eluted with mixture of hexane, ethyl acetate and ethanol (60:35:5, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain

30



(0.40g).


NMR (CDCl₃, δ) 0.75-1.1 (m, 24H), 1.4-1.85 (m, 18H), 2.7-3.1 (m, 28H), 4.4-5.8 (m, 8H), 6.64 (d, 4H), 7.08 (d, 4H)

35 IR (KBr): 1741, 1662cm⁻¹

FAB-MS : 1035 [M + H]⁺

Example 4


40



45

(0.145g) was dissolved in 4N-hydrogen chloride in ethyl acetate (2ml). The solvent was evaporated in vacuo, the residue was dissolved in 4N-hydrogen chloride in ethyl acetate (2ml) again. After the solvent was evaporated in vacuo, azeotroped by toluene (10ml) twice to give

50




55 2HCl (0.157g).

NMR (CDCl₃, δ) 0.7-1.1 (m, 24H), 1.25-1.85 (m, 18H), 2.8-3.4 (m, 16H), 3.15 (bs, 12H), 4.6-5.75 (m, 8H), 7.35-7.5 (m, 4H), 7.6-7.75 (m, 4H)

IR (KBr): 1742, 1649cm⁻¹

Example 5

To a solution of 3HCl•H-MeLeu-D-p-MorPhLac-MeLeu-D-Lac - MeLeu-D-p-MorPhLac-MeLeu-D-Lac-OH (0.404g) in dichloromethane (162ml) were added sodium bicarbonate (0.27g) and bis(2-oxo-3-oxazolidinyl)-phosphinic chloride (0.13g), and stirred for 71 hours successively. The solvent was evaporated in vacuo, added water (50ml), and extracted with ethyl acetate (50ml x 3). The ethyl acetate layer was washed with saturated brine, dried over anhydrous sodium sulfate. The solvent was evaporated in vacuo, the resultant crude product was purified by silica gel chromatography, and eluted with mixture of hexane, ethyl acetate, and ethanol (50:45:5, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain



15

(0.238g).


NMR (CDCl₃, δ) 0.8-1.1 (m, 24H), 1.3-1.8 (m, 18H), 2.7-3.2 (m, 24H), 3.8-3.9 (m, 8H), 4.4-4.55 (m) and 5.0-5.7 (m) (8H), 6.82 (d, 4H), 7.13 (d, 4H)

IR (KBr): 1740, 1662 cm⁻¹

20 FAB-MS : 1119 [M + H]⁺

Example 6

3HCl•H-MeLeu-D-p-PyrPhLac-MeLeu-D-Lac-MeLeu-D-p-PyrPhLac-MeLeu-D-Lac-OH (0.80g) was used instead of 3HCl•H-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-OH. Except above matter.



30

(0.238g) was obtained according to a similar manner to that of Example 5.


NMR (CDCl₃, δ) 0.75-1.1 (m, 24H), 1.2-1.8 (m, 18H), 1.9-2.05 (m, 8H), 2.7-3.1 (m, 16H), 3.15-3.3 (m, 8H), 4.4-4.55 (m) and 5.0-5.7 (m) (8H), 6.46 (d, 4H), 7.06 (d, 4H)

35 IR (KBr): 1740, 1664 cm⁻¹

FAB-MS : 1087 [M + H]⁺

Example 7


40



45

(0.382g) was cooled down to -10 °C. After fuming nitric acid (3.5ml) was added dropwise in 15 minutes, the mixture was stirred for one hour at room temperature. The reaction solution was added gradually into saturated sodium bicarbonate (25ml), and extracted with ethyl acetate (25ml x 3). After washing the ethyl acetate layer with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated in vacuo to give crude product of

50



55

(0.465g).


NMR (CDCl₃, δ) 0.65-1.1 (m, 24H), 1.2-1.8 (m, 18H), 2.7-3.3 (m, 16H), 4.4-4.55 (m) and 5.0-5.7 (m) (8H), 7.35-7.55 (m, 4H), 8.05-8.15 (m, 4H)

IR (KBr): 1742,1662,1519,1343cm⁻¹


FAB-MS: 1039 [M + H]⁺

Example 8

To a ethanol (5ml) solution of crude product (72mg) of



were added 37% aqueous formaldehyde (0.4ml) and 10% palladium on carbon (0.1g), and hydrogenated for 2 hours at room temperature under hydrogen gas atmospheric pressure. The catalyst was filtered off and the crude product which was gained by evaporating the solvent was purified by silica gel column chromatography, eluting with a mixed solvent of hexane, ethyl acetate and ethanol (75:20:5, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain




(42mg).

NMR (CDCl₃, δ) 0.75-1.1 (m, 24H), 1.4-1.85 (m, 18H), 2.7-3.1 (m, 28H), 4.4-5.8 (m, 8H), 6.64 (d, 4H), 7.08 (d, 4H)


IR (KBr): 1741, 1662cm⁻¹

Example 9

To a methanol (10ml) solution of crude product (312mg) of



was added 10% palladium on carbon (0.1g), and hydrogenated for 2 hours at room temperature under hydrogen gas atmospheric pressure. The catalyst was filtered off and the crude product which was gained by evaporating the solvent was purified by silica gel column chromatography, eluting with a mixed solvent of hexane, ethyl acetate and ethanol (40:55:5, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain



(144mg).


NMR (CDCl₃, δ) 0.75-1.1 (m, 24H), 1.4-1.85 (m, 18H), 2.7-3.1 (m, 16H), 4.4-5.8 (m, 8H), 6.64 (d, 4H), 7.08 (d, 4H)

IR (KBr): 1741, 1662cm⁻¹


FAB-MS: 979 [M + H]⁺

Example 10

To a methanol (10ml) solution of




5 (250mg) were added acetaldehyde (0.56g) and 10% palladium on carbon (0.15g), and hydrogenated for 4 hours at room temperature under hydrogen gas atmospheric pressure. The catalyst was filtered off and the crude product which was gained by evaporating the solvent was purified by silica gel column chromatography, eluting with a mixed solvent of hexane, ethyl acetate, and ethanol (25:20:5, v/v). The fractions
10 containing the desired product were combined and evaporated in vacuo to obtain




15 (147mg).
NMR (CDCl₃, δ) :0.7-1.9 (m, 54H), 2.65-3.1 (m, 12H), 3.2-3.4 (m, 8H), 4.4-4.5 (m) and 5.0-5.8 (m) (8H), 6.45-6.6 (m, 4H), 7.0-7.1 (m, 4H)
IR (KBr): 1741, 1662 cm⁻¹
20 FAB-MS: 1091 [M + H]⁺

Example 11

To a methanol (10ml) solution of




30 (250mg) were added n-hexanal (0.62g) and 10% palladium on carbon (0.15g), and hydrogenated for 11 hours at room temperature under hydrogen gas atmospheric pressure. The catalyst was filtered off and the crude product which was gained by evaporating the solvent was purified by silica gel column chromatography, eluting with a mixed solvent of hexane, ethyl acetate, and ethanol (25:70:5, v/v). The fractions
35 containing the desired product were combined and evaporated in vacuo. To the resultant residue was added 4N-hydrogen chloride in ethyl acetate (5ml), and the solvent was evaporated, repeated the same procedure again to give



2HCl (147mg).
NMR (CDCl₃, δ) :0.7-2.1 (m, 86H), 2.7-3.6 (m, 24H), 4.4-4.6 (m) and 5.0-5.7 (m) (8H), 7.3-7.45 (m, 4H), 7.6-7.75 (m, 4H)
45 IR (KBr): 1743, 1656 cm⁻¹
FAB-MS: 1315 [M + H]⁺

Example 12

50 3HCl•H-MeLeu-D-p-PipPhLac-MeLeu-D-Lac-MeLeu-D-p-PipPhLac-MeLeu-D-Lac-OH (1.24g) was used instead of 3HCl•H-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-OH. Except above matter,



(0.82g) was obtained according to a similar manner to that of Example 5.


NMR (CDCl₃, δ) :0.7-1.1 (m,24H),1.2-1.9 (m,30H),2.65-3.2 (m,24H), 4.4-4.55 (m) and 5.0-5.7 (m) (8H),6.84 (d,4H),7.09 (d,4H)

IR (KBr):1740,1663cm⁻¹


5 FAB-MS:1115 [M + H]⁺

Example 13

A suspension of



15 (0.228g), 2,5-dimethoxytetrahydrofuran (0.045ml) and acetic acid (1ml) were stirred for 3 hours at room temperature, and further stirred for 3 hours at 50°C. Further more, to the mixture was added 2,5-dimethoxytetrahydrofuran (0.045ml) and stirred for 3 hours successively. The reaction solution was poured into ice-aqueous saturated sodium bicarbonate solution and extracted with ethyl acetate (20ml × 2). After
20 washing the ethyl acetate layer with saturated brine, dried over anhydrous sodium sulfate, the crude product which was gained by evaporating the solvent was purified by silica gel column chromatography, eluting with a mixed solvent of hexane, ethyl acetate, and ethanol (50:45:5, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain



(56.6mg).


30 NMR (CDCl₃, δ) :0.77-1.1 (m,24H),1.2-1.82 (m,18H),2.7-3.23 (m,16H),5.2-5.73 (m,8H),6.28-6.39 (m,4H),6.56-6.7 (m,4H),6.96-7.38 (m,8H)

IR (KBr):1742,1663cm⁻¹


FAB-MS:1079 [M + H]⁺

35 Example 14

To a trifluoroacetic acid (0.5ml) solution of



(48mg) was added at room temperature, sodium nitrite (8mg), after the reaction solution was stirred for 1 hour at 60°C, the solvent was evaporated in vacuo and the residue was azeotroped by toluene. To the
45 residue were added sodium bicarbonate (84mg), water (0.5ml), dioxane (2.5ml) and after the mixture was stirred for 15 hours at room temperature, water (50ml) was added and extracted with ethyl acetate (25ml × 3). After washing the ethyl acetate layer with saturated brine, dried over anhydrous sodium sulfate, the crude product which was gained by evaporating the solvent was purified by silica gel column chromatography, eluting with a mixed solvent of hexane, ethyl acetate, and ethanol (65:30:5, v/v). The fractions
50 containing the desired product were combined and evaporated in vacuo to obtain




(40.4mg).

NMR (CDCl₃, δ) :0.70-1.8 (m,42H),2.7-3.15 (m,16H),4.38-4.55 (m) and 4.97-5.68 (m) (8H),6.65-6.83 (m,4H)-


,6.94-7.17 (m,4H)
 IR (KBr):1741,1648cm⁻¹
 FAB-MS:981 [M + H]⁺

5 Example 15

A suspension of



(0.3g), dimethylformamide (2ml), potassium carbonate (128.5mg) and ethyl iodide (0.08ml) were stirred for 18 hours at room temperature, and then water (30ml) was added and extracted with ethyl acetate (20ml x 3). After washing the ethyl acetate layer with saturated brine, dried over anhydrous sodium sulfate, the crude product which was gained by evaporating the solvent was purified by silica gel column chromatography, eluting with a mixed solvent of hexane and ethyl acetate (1:1, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain



25 (0.188g).


NMR (CDCl₃, δ) :0.76-1.09 (m,24H),1.3-1.82 (m,16H),2.7-3.15 (m,16H),3.99 (q,4H),4.4-4.58 (m) and 4.9-5.8 (m) (8H),6.76-6.88 (m,4H), 7.07-7.39 (m,4H)

IR (KBr):1743,1664cm⁻¹

30 FAB-MS:1037 [M + H]⁺

Example 16

n-Hexyl bromide (0.25ml) was used instead of ethyl iodide. Except above matter,



40 (0.179g) was obtained according to a similar manner to that of Example 15.


NMR (CDCl₃, δ) :0.70-1.9 (m,64H),2.68-3.2 (m,16H),3.91 (t,4H), 4.42-4.56 (m) and 5.03-5.9 (m) (8H),6.69-6.84 (m,4H),7.05-7.2 (m,4H)

IR (KBr):1742,1661cm⁻¹

FAB-MS:1149 [M + H]⁺

45 Example 17

To Boc-MeLeu-D-p-MEPHlac-MeLeu-D-Lac-MeLeu-D-p-MEPHlac-MeLeu-D-Lac-OH (1.03g) was added 4N-hydrogen chloride in ethyl acetate solution (20ml), and stirred for 50 minutes at 0 °C. After the solvent was evaporated in vacuo, the residue was azeotroped by toluene, was added dichloromethane (850ml), cooled down to 0 °C, added triethylamine (0.47ml) and bis (2-oxo-3-oxazolidinyl)phosphinic chloride (0.32g), and stirred for 14 hours successively. The solvent was evaporated in vacuo, was added 5% citric acid (100ml) and extracted with ethyl acetate (100ml x 2). After washing the ethyl acetate layer with aqueous saturated sodium bicarbonate and saturated brine, dried over anhydrous sodium sulfate, the crude product which was gained by evaporating the solvent was purified by silica gel column chromatography, eluting with a mixed solvent of hexane, ethyl acetate, and ethanol (60:35:5, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain



(0.506g).


NMR (CDCl_3, δ): 0.78-1.08 (m, 24H), 1.2-1.9 (m, 18H), 2.62-3.09 (m, 16H), 3.45 (s, 6H), 3.65-3.82 (m, 4H), 4.02-4.19 (m, 4H), 4.6-4.78 (m) and 5.01-5.7 (m) (8H), 6.8-6.96 (m, 4H), 7.12-7.22 (m, 4H)

IR (KBr): 1740, 1662 cm^{-1}


FAB-MS: 1097 $[\text{M} + \text{H}]^+$

Example 18

A suspension of



(0.3g), dimethylformamide (2ml), potassium carbonate (128.5mg), 1-bromo-2-(2-methoxyethoxy)ethane (0.93ml), and sodium iodide (92.9mg) were stirred for 17 hours at room temperature and stirred for 24 hours at 50 °C. Further, to the mixture was added sodium iodide (92.9mg) and stirred for 8 hours successively. To the mixture was added water (30ml) and extracted with ether (20ml \times 3). After washing the ether layer with saturated brine, dried over anhydrous sodium sulfate, the crude product which was gained by evaporating the solvent was purified by silica gel column chromatography and eluting with a mixed solvent of hexane, ethyl acetate, and ethanol (30:65:5, v/v). The fractions containing the desired product were combined and evaporated in vacuo to obtain



(0.105g).


NMR (CDCl_3, δ): 0.71-1.82 (m, 54H), 2.84-3.23 (m, 16H), 3.39 (s, 6H), 3.59-3.63 (m, 4H), 3.63-3.79 (m, 4H), 3.79-3.92 (m, 4H), 4.03-4.2 (m, 4H), 4.39-4.56 (m) and 5.0-5.77 (m) (8H), 6.83 (d, 4H), 7.13 (d, 4H)

IR (KBr): 1743, 1662 cm^{-1}

FAB-MS: 1185 $[\text{M} + \text{H}]^+$

Example 19

Boc-MeLeu-D-o-MeOPHac-MeLeu-D-Lac-MeLeu-D-o-MeOPHac-MeLeu-D-Lac-OH (1.24g) was used instead of Boc-MeLeu-D-p-MEPHac-MeLeu-D-Lac-MeLeu-D-p-MEPHac-MeLeu-D-Lac-OH. Except above matter,



(0.87g) was obtained according to a similar manner to that of Example 17.


NMR (CDCl_3, δ): 0.79-1.08 (m, 24H), 1.20-1.81 (m, 18H), 2.71-3.15 (m, 16H), 3.85 (s) and 3.86 (s) (6H), 4.40-5.89 (m, 8H), 6.82-6.93 (m, 4H), 7.12-7.27 (m, 4H)

IR (KBr): 1741, 1663 cm^{-1}

FAB-MS: 1009 $[\text{M} + \text{H}]^+$

Example 20

Boc-MeLeu-D-m-MeOPhLac-MeLeu-D-Lac-MeLeu-D-m-MeOPhLac-MeLeu-D-Lac-OH (0.79g) was used instead of Boc-MeLeu-D-p-MEPHLac-MeLeu-D-Lac-MeLeu-D-p-MEPHLac-MeLeu-D-Lac-OH. Except above matter,



(0.51g) was obtained according to a similar manner to that of Example 17.


NMR (CDCl₃, δ) : 0.75-1.15 (m, 24H), 1.20-1.85 (m, 18H), 2.70-3.18 (m, 16H), 3.78 (s, 6H), 4.40-5.78 (m, 8H), 6.70-6.88 (m, 6H), 7.10-7.25 (m, 2H)

IR (KBr): 1739, 1661 cm⁻¹

FAB-MS: 1009 [M + H]⁺

Example 21

Boc-MeLeu-D-3,4-DMOPhLac-MeLeu-D-Lac-MeLeu-D-3,4-DMOPhLac-MeLeu-D-Lac-OH (0.26g) was used instead of Boc-MeLeu-D-p-MEPHLac-MeLeu-D-Lac-MeLeu-D-p-MEPHLac-MeLeu-D-Lac-OH. Except above matter,



(0.14g) was obtained according to a similar manner to that of Example 17.


NMR (CDCl₃, δ) : 0.72-1.00 (m, 24H), 1.21-1.80 (m, 18H), 2.72-3.15 (m, 16H), 3.85 (s, 6H), 3.86 (s, 6H), 4.42-5.72 (m, 8H), 6.72-6.81 (m, 6H)

IR (KBr): 1740, 1661 cm⁻¹

FAB-MS: 1069 [M + H]⁺

Example 22

Boc-MeLeu-D-2,4-DMOPhLac-MeLeu-D-Lac-MeLeu-D-2,4-MOPhLac-MeLeu-D-Lac-OH (1.49g) was used instead of Boc-MeLeu-D-p-MEPHLac-MeLeu-D-Lac-MeLeu-D-p-MEPHLac-MeLeu-D-Lac-OH. Except above matter,



(0.95g) was obtained according to a similar manner to that of Example 17.

NMR (CDCl₃, δ) : 0.78-1.12 (m, 24H), 1.20-1.80 (m, 18H), 2.70-3.16 (m, 16H), 3.75-3.90 (m, 12H), 4.40-5.83 (m, 8H), 6.35-6.43 (m, 4H), 7.01-7.12 (m, 2H)

IR (KBr): 1740, 1661 cm⁻¹

FAB-MS: 1069 [M + H]⁺

Example 23

Boc-MeLeu-D-3,4-MODPhLac-MeLeu-D-Lac-MeLeu-D-3,4-MODPhLac-MeLeu-D-Lac-OH (0.59g) was used instead of Boc-MeLeu-D-p-MEPHLac-MeLeu-D-Lac-MeLeu-D-p-MEPHLac-MeLeu-D-Lac-OH. Except above matter,

MeLeu-D-3,4-MODPhLac-MeLeu-D-Lac-MeLeu-D-3,4-MODPhLac-MeLeu-D-Lac

- 5 (0.29g) was obtained according to a similar manner to that of Example 17.
 NMR (CDCl_3, δ): 0.80-1.12 (m, 24H), 1.22-2.00 (m, 18H), 2.63-3.20 (m, 16H), 4.35-4.53 (m) and 5.00-5.70 (m) (8H), 5.82-6.00 (m, 4H), 6.60-6.82 (m, 6H)
 IR (KBr): 1740, 1661 cm^{-1}
 FAB-MS: 1037 $[\text{M} + \text{H}]^+$

10 Example 24

- 3HCl • H-MeLeu-D-3MA-4MOPhLac-MeLeu-D-Lac-MeLeu-D-3MA-4MOPhLac-MeLeu-D-Lac-OH (1.18g) was used instead of 3HCl • H-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-OH. Except above matter,

MeLeu-D-3MA-4MOPhLac-MeLeu-D-Lac-MeLeu-D-3MA-4MOPhLac-MeLeu-D-Lac

- 20 (0.390g) was obtained according to a similar manner to that of Example 5.
 NMR (CDCl_3, δ): 0.75-1.1 (m, 24H), 1.2-2.1 (m, 18H), 2.6-3.3 (m, 28H), 3.85 (s, 6H), 4.4-4.55 (m) and 5.0-5.7 (m) (8H), 6.7-6.9 (m, 6H)
 25 IR (KBr): 1741, 1663 cm^{-1}
 FAB-MS: 1095 $[\text{M} + \text{H}]^+$

Example 25

- 30 Boc-MeLeu-D-3,4-DMAPhLac-MeLeu-D-Lac-MeLeu-D-3,4-DMAPhLac-MeLeu-D-Lac-OH (0.35g) was used instead of Boc-MeLeu-D-p-MEPhLac-MeLeu-D-Lac-MeLeu-D-p-MEPhLac-MeLeu-13-Lac-OH, and N-methylmorpholine (0.186ml) was used instead of triethylamine. Except above matter,

MeLeu-D-3,4-DMAPhLac-MeLeu-D-Lac-MeLeu-D-3,4-DMAPhLac-MeLeu-D-Lac

- 35 (0.19g) was obtained according to a similar manner to that of Example 17.
 40 NMR (CDCl_3, δ): 0.70-1.10 (m, 24H), 1.15-1.90 (m, 18H), 2.68-3.20 (m, 40H), 4.39-4.60 (m) and 4.95-5.75 (m) (8H), 6.65-6.80 (m, 6H)
 IR (KBr): 1739, 1662 cm^{-1}
 FAB-MS: 1121 $[\text{M} + \text{H}]^+$

45 Example 26


- Boc-MeLeu-D-o-FPhLac-MeLeu-D-Lac-MeLeu-D-o-FPhLac-MeLeu-D-Lac-OH (0.82g) was used instead of Boc-MeLeu-D-p-MEPhLac-MeLeu-D-Lac-MeLeu-D-p-MEPhLac-MeLeu-D-Lac-OH. Except above matter,

MeLeu-D-o-FPhLac-MeLeu-D-Lac-MeLeu-D-o-FPhLac-MeLeu-D-Lac

- 50 (0.58g) was obtained according to a similar manner to that of Example 17.
 55 NMR (CDCl_3, δ): 0.64-1.13 (m, 24H), 1.21-1.83 (m, 18H), 2.63-3.22 (m, 16H), 4.4-4.57 (m) and 5.02-5.82 (m) (8H), 6.98-7.38 (m, 8H)
 IR (KBr): 1743, 1663 cm^{-1}
 FAB-MS: 985 $[\text{M} + \text{H}]^+$

Example 27

Boc-MeLeu-D-m-FPhLac-MeLeu-D-Lac-MeLeu-D-m-FPhLac-MeLeu-D-Lac-OH (0.77g) was used instead of Boc-MeLeu-D-p-MEPhLac-MeLeu-D-Lac-MeLeu-D-p-MEPhLac-MeLeu-D-Lac-OH. Except above matter,



(0.534g) was obtained according to a similar manner to that of Example 17.


NMR (CDCl_3, δ): 0.7-1.06 (m, 24H), 1.1-1.95 (m, 18H), 2.6-3.27 (m, 16H), 4.4-4.58 (m) and 5.0-5.78 (m) (8H), 6.82-7.1 (m, 6H), 7.18-7.38 (m, 2H)

IR (KBr): 1741, 1663 cm^{-1}

FAB-MS: 985 $[\text{M} + \text{H}]^+$

Example 28

Boc-MeLeu-D-p-FPhLac-MeLeu-D-Lac-MeLeu-D-p-FPhLac-MeLeu-D-Lac-OH (0.99g) was used instead of Boc-MeLeu-D-p-MEPhLac-MeLeu-D-Lac-MeLeu-D-p-MEPhLac-MeLeu-D-Lac-OH. Except above matter,



(0.686g) was obtained according to a similar manner to that of Example 17.

NMR (CDCl_3, δ): 0.7-1.1 (m, 24H), 1.18-1.9 (m, 18H), 2.62-3.23 (m, 16H), 4.4-4.58 (m) and 5.0-5.75 (m) (8H), 6.89-7.07 (m, 4H), 7.07-7.25 (m, 4H)

IR (KBr): 1741, 1662 cm^{-1}

FAB-MS: 985 $[\text{M} + \text{H}]^+$

Example 29

Boc-MeLeu-D-p-MeOPhLac-MeLeu-D-Lac-MeLeu-D-PhLac-MeLeu-D-Lac-OH (0.96g) was used instead of Boc-MeLeu-D-p-MEPhLac-MeLeu-D-Lac-MeLeu-D-p-MEPhLac-MeLeu-D-Lac-OH. Except above matter,



(0.461g) was obtained according to a similar manner to that of Example 17.


NMR (CDCl_3, δ): 0.78-1.06 (m, 24H), 1.3-1.82 (m, 18H), 2.64-3.21 (m, 16H), 3.78 (s, 3H), 4.6-4.78 (m) and 5.02-5.8 (m) (8H), 6.78-6.93 (m, 2H), 7.1-7.4 (m, 7H)

IR (KBr): 1741, 1663 cm^{-1}

FAB-MS: 979 $[\text{M} + \text{H}]^+$

Example 30

HCl·H-MeLeu-D-p-MeOPhLac-MeLeu-Glycol-MeLeu-D-p-MeOPhLac-MeLeu-Glycol-OH (0.52g) was used instead of HCl·H-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-MeLeu-D-p-MorPhLac-MeLeu-D-Lac-OH. Except above matter,



(0.26g) was obtained according to a similar manner to that of Example 5.

NMR (CDCl_3, δ): 0.75-1.1 (m, 24H), 1.2-1.8 (m, 12H), 2.7-3.2 (m, 16H), 3.78 (s, 3H), 3.79 (s, 3H), 4.2-5.8 (m, 10H), 6.75-6.9 (m, 4H), 7.05-7.2 (m, 4H)

IR (KBr): 1741, 1663 cm^{-1}

5 FAB-MS: 981 $[\text{M} + \text{H}]^+$

Example 31

10 To an aqueous suspension (5ml) of oxydiacetaldehyde bis (diethylacetal) (0.50g) was added five drops of acetic acid and heated for half an hour at 100 °C. To the resultant oxydiacetaldehyde solution was added acetonitrile solution (5ml) of

15 $\text{MeLeu-D-p-NH}_2\text{PhLac-MeLeu-D-Lac-MeLeu-D-p-NH}_2\text{PhLac-MeLeu-D-Lac}$

(0.198g) and after stirring for half an hour at room temperature, adjusted to pH7.0 by aqueous saturated sodium bicarbonate solution. To the mixture was added sodium cyanoborohydride (0.055g) and pH was kept under 7.5 with acetic acid and in the meanwhile, it was stirred for 2 hours at room temperature. To the resultant reaction solution was added water (50ml) and aqueous saturated sodium bicarbonate solution (5ml), and extracted with ethyl acetate. After washing the ethyl acetate layer with saturated brine, dried over anhydrous sodium sulfate. The solvent was evaporated in vacuo, the resultant crude product was purified by silica gel chromatography, and eluted with mixture of hexane, ethyl acetate, and ethanol (55:40:5, v/v).
25 The fractions containing the desired product were combined and evaporated in vacuo to obtain

$\text{MeLeu-D-p-MorPhLac-MeLeu-D-Lac-MeLeu-D-p-MorPhLac-MeLeu-D-Lac}$

30 (0.045g).


NMR (CDCl_3, δ): 0.8-1.1 (m, 24H), 1.3-1.8 (m, 18H), 2.7-3.2 (m, 24H), 3.8-3.9 (m, 8H), 4.4-4.55 (m) and 5.0-5.7 (m) (8H), 6.82 (d, 4H), 7.13 (d, 4H)

IR (KBr): 1740, 1662 cm^{-1}

35 FAB-MS: 1119 $[\text{M} + \text{H}]^+$

Claims

1. A compound of the general formula (I):



50 wherein A is benzyl group which has suitable substituent(s) or phenyl group which may have suitable substituent(s),

A^a is benzyl group which may have suitable substituent(s) or phenyl group which may have suitable substituent(s),

55 B and D are each lower alkyl,

C is hydrogen or lower alkyl,


and a pharmaceutically acceptable salt thereof.

2. A compound of claim 1, wherein A and A^a are each benzyl group which has cyclic amino, dilower alkylamino or lower alkoxy, B and D are each isopropyl, C is methyl.


- 5 3. A compound of claim 1, wherein A and A^a are each benzyl group which has morpholino, dimethylamino or methoxy.

4. A compound of claim 1, wherein A and A^a are each benzyl group which has amino, nitro or hydroxy, B and D are each isopropyl, C is methyl.


5. A compound of the formula :




6. A compound of the formula :



7. A process for preparation of a compound of the general formula :




or a salt thereof,
which comprises
subjecting a compound of the general formula :




or a salt thereof, to monoalkylation reaction followed by intramolecular reaction,
wherein B and D are each lower alkyl,
C is hydrogen or lower alkyl,
A³ is benzyl group which has amino, or benzyl group which has amino and lower alkoxy,
A⁵ is benzyl group which has cyclic amino, or benzyl group which has cyclic amino and lower alkoxy,

- 55 8. A process for preparation of a compound of the general formula:



10
or a salt thereof,
which comprises
subjecting a compound of the general formula :



25
or a salt thereof, to alkylation reaction,
wherein B and D are each lower alkyl,

C is hydrogen or lower alkyl, A³ is benzyl group which has amino, or benzyl group which has
amino and lower alkoxy,

30
A⁴ is benzyl group which has mono- or di- lower alkylamino, or benzyl group which has mono- or di-
lower alkylamino and lower alkoxy,

9. An anthelmintic agent which comprises a compound or a pharmaceutically acceptable salt thereof of
claim 1 as an active ingredients.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP93/00286

A. CLASSIFICATION OF SUBJECT MATTER Int. Cl. ⁵ C07D273/00, 413/10, 417/10, 487/04, 487/08, A61K31/395 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int. Cl. ⁵ C07D273/00, 413/10, 417/10, 487/04, 487/08, A61K31/395 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS Online		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	JP, A, 3-35796 (Meiji Seika Kaisha, Ltd.), February 15, 1991 (15. 02. 91), Claims 1, 4 & EP, A, 382173 & US, A, 5116815	1, 9 2-8
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>		
Date of the actual completion of the international search April 28, 1993 (28. 04. 93)		Date of mailing of the international search report May 25, 1993 (25. 05. 93)
Name and mailing address of the ISA/ Japanese Patent Office Facsimile No.		Authorized officer Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)